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ABSTRACT OF THE DISSERTATION
Refining Associations between Targeted Genes and the
Development of Substance Use Disorders
by
Emily Olfson
Doctor of Philosophy in Biology and Biomedical Sciences
Human and Statistical Genetics
Washington University in St. Louis, 2016
Professor Laura J. Bierut, Chair
Recent genome-wide association studies (GWAS) provide strong evidence for the contribution
of a few specific genes to alcohol and nicotine dependence. Chapter 2 explores numerous
previously identified candidate genes for alcohol dependence using a publically available
GWAS. I found that many candidate loci do not replicate, highlighting the utility of GWAS for
focusing on disease associated genes. Chapters 3-5 dissect associations between three genomewide significant genes and substance use disorders. Chapter 3 focuses on a functional variant in
alcohol dehydrogenase (ADH) 1B. Through examining 1,550 adolescent drinkers in the
Collaborative Study on the Genetics of Alcoholism (COGA), I extended adult findings by
showing that this ADH1B variant protected against early drinking milestones. Furthermore, I
provided evidence for a gene-by-environment interaction where best friends drinking eliminated
this genetic protective effect, illustrating the important interplay between genetic and
environmental factors in the development of drinking behaviors. Chapter 4 examines variation in
the nicotine metabolizing cytochrome P450 gene CYP2A6. Previous studies show slow
metabolizers smoke fewer cigarettes, but provide conflicting results on the role of CYP2A6 in
ix

nicotine dependence. Using a COGA young adult sample, I found that CYP2A6 metabolism was
not associated with smoking initiation or daily smoking, but among daily smokers, slow
metabolism was associated with increased risk of dependence. This association was replicated in
an independent sample from the Collaborative Study of Nicotine Dependence, adding insight
into the complex role of CYP2A6 across stages of smoking behaviors. Chapter 5 focuses on
coding variation in the α5 nicotinic receptor subunit gene (CHRNA5), which harbors a
nonsynonymous common variant robustly associated with nicotine dependence. I examined
targeted sequence data of CHRNA5 from approximately 3,000 nicotine dependent cases and
controls, with independent replication of common and low frequency variants in 12 studies. I
found that common, low frequency, and rare CHRNA5 coding variants were independently
associated with increased nicotine dependence risk. Incorporating coding variants beyond the
well-studied common variant increased the variance in nicotine dependence explained by
CHRNA5. Overall, this dissertation advances our understanding of targeted genes for substance
use disorders by incorporating important environments, critical developmental periods, and rare
variants.

x

“The ideal art, the noblest of art: working with the complexities of life, refusing to simplify, to
‘overcome’ doubt.”

-Joyce Carol Oates
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CHAPTER ONE:
Introduction: Substance use disorders are complex diseases
with important public health implications
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1.1 THE PUBLIC HEALTH BURDEN OF SUBSTANCE USE DISORDERS
Substance use disorders are a leading cause of preventable death in both the United States
and worldwide. Each year, 3.3 million people die due to the harmful effects of alcohol,
representing 5.9% of all deaths across the world (WHO, 2014b). From 2006-2010,
approximately 88,000 deaths and 2.5 million years of potential life were lost in the United States
due to alcohol consumption (Stahre et al., 2014). Heavy drinking can have immediate health
related effects through injuries, violence, alcohol poisoning, and risky sexual behaviors. Over
time, excessive alcohol use can lead to several chronic diseases, including heart disease, liver
disease, cancer, and mental health problems. Tobacco smoking similarly causes many chronic
diseases, including heart disease, lung cancer, and respiratory illnesses. Nearly 6 million people
die each year from tobacco products worldwide (WHO, 2014a). In the United States alone,
cigarette smoking causes about one of every five deaths each year, accounting for approximately
480,000 deaths annually (CDC, 2014). Beyond excessive morbidity and mortality associated
with these behaviors, economically society pays a high price for substance use. Approximately
11% of the total federal and state government budget is spent on the consequences of alcohol,
tobacco, and other drug use (CASAColumbia, 2009).

3

1.2 GENES INFLUENCE SUBSTANCE USE DISORDERS
Genetic factors have long been recognized to influence the development of substance use
disorders. Twin studies estimate that the heritability of substance dependence is approximately
50%-60% (Heath et al., 1997, Kendler et al., 2003, Knopik et al., 2004, Li, 2006). Candidate
gene studies have identified hundreds of genes potentially associated with substance use
disorders (Yu et al.). More recently, large-scale genome wide association (GWA) studies have
confirmed the contribution of a few specific genes to alcoholism and smoking (Wang et al.,
2012, Rietschel and Treutlein, 2013).
Genes with the clearest associations with alcoholism produce metabolizing enzymes
(Edenberg and Foroud, 2013, Hurley and Edenberg, 2012). Alcohol is primarily metabolized in
the liver, and the first step is the oxidation of ethanol to acetaldehyde. Acetaldehyde is a toxic
intermediate, and systemic build-up leads to unpleasant feelings, such as dizziness, nausea, and
tachycardia. This process is catalyzed by alcohol dehydrogenases (ADH), which are a class of
enzymes encoded by seven genes on chromosome 4. The enzyme encoded by ADH1B has the
highest concentration in adult livers, and the ADH1B rs1229984 variant has reached genomewide significance levels for alcohol dependence across different ancestry populations (Li et al.,
2011, Li et al., 2012, Bierut et al., 2012, Gelernter et al., 2014). The minor A allele of rs1229984
causes an amino acid change at position 48 that increases the rate of oxidation of alcohol and
leads to transient increases in acetaldehyde. Given the toxicity of acetaldehyde, negative effects
are experienced by people with this ADH1B variant when they consume alcohol, which
discourages heavy drinking.
Similar to alcoholism, nicotine metabolism genes are important for the development of
smoking behaviors. The cytochrome P450 enzyme CYP2A6 is responsible for the majority of
4

oxidation of nicotine to cotinine, which is the primary pathway of nicotine metabolism
(Hukkanen et al., 2005). The region on chromosome 19 that harbors the CYP2A6 gene is
genome-wide significant in large meta-analyses focused on cigarettes per day (Thorgeirsson et
al., 2010, TAG, 2010). Among nicotine dependent adults, the majority of studies support that
genetically slower metabolizers smoke fewer cigarettes per day (Benowitz, 2008), reflecting the
fact that smokers titrate their cigarette consumption to maintain certain nicotine levels. However,
studies in youth present conflicting results on the effect of nicotine metabolism on the
development of nicotine dependence and other smoking behaviors (Audrain-McGovern et al.,
2007, Huang et al., 2005, Moolchan et al., 2009, O'Loughlin et al., 2004, Rubinstein et al., 2013,
Rubinstein et al., 2008). One challenge to studying CYP2A6 is that the locus is highly
polymorphic with functionally diverse alleles. Recently, Bloom et al. (2011) developed a
metabolism metric to predict nicotine metabolism based on different CYP2A6 haplotypes. This
metric predicts approximately 70% of the variance in metabolism of orally administered nicotine
to cotinine in European Americans.
The strongest genetic contribution to nicotine dependence comes from variation in
nicotinic receptor subunit genes. The physiological effects of nicotine are produced through the
neuronal nicotinic acetylcholine receptors (nAChRs) (Dani and De Biasi, 2001), which are
pentamiric catonic channels primarily composed of combinations of α and β subunits. Several
independent studies have demonstrated that the nonsynonymous rs16969968 variant in the α5
subunit gene (CHRNA5) is associated with a variety of smoking behaviors (Saccone et al., 2007,
Berrettini et al., 2008, Weiss et al., 2008, Stevens et al., 2008, Sherva et al., 2008, Baker et al.,
2009, Keskitalo et al., 2009). Subsequently, this association has been reported as the most
significant in genome-wide meta-analyses of cigarettes per day (p=5.57x10-72) (Thorgeirsson et
5

al., 2010, TAG, 2010, Liu et al., 2010). Additional studies have extended this association with
rs16969968 to smoking-related illnesses, including lung cancer and chronic obstructive
pulmonary disease (Amos et al., 2008, Hung et al., 2008, Pillai et al., 2009, Thorgeirsson et al.,
2008). This association likely reflects greater exposure to carcinogens in tobacco smoke in
response to higher levels of nicotine dependence. Nicotinic receptors containing α5 subunits
normally activate the interpeduncular pathway in response to nicotine intake, which discourages
high levels of cigarette consumption (Fowler et al., 2011). The rs169669968 variant causes an
amino acid change at position 398, and functional studies show that this change decreases
receptor function (Bierut et al., 2008, Kuryatov et al., 2011). Decreased function of α5
containing receptors is hypothesized to prevent negative feedback in response to cigarette
consumption, leading to heavy smoking.

6

1.3 SCOPE OF THE DISSERTATION
The primary goal of my dissertation is to improve our understanding of how targeted
genes contribute to substance use disorders.
Chapter 2 examines well-studied candidate genes for alcohol dependence using a GWA
study comparing alcohol dependent cases and controls. These targeted candidate genes were
selected using the Human Genome Epidemiology Navigator, which catalogues published genetic
association studies (Yu et al., 2008). Our findings suggest that several extensively studied
candidate loci do not strongly contribute to risk of developing alcohol dependence. This chapter
has been published in the Journal Alcoholism: Clinical and Experimental Research (Olfson and
Bierut, 2012).
Olfson E, Bierut LJ. Convergence of genome-wide association and candidate gene
studies for alcoholism. Alcohol Clin Exp Res 2012 36(12):2086-2094. PMCID:
PMC3521088

Chapter 3 focuses on the interplay between the ADH1B rs1229984 variant and the
critical social environment of peer drinking in the development of adolescent drinking behaviors.
Through examining 1,550 European and African American youth enrolled in the Collaborative
Study on the Genetics of Alcoholism (COGA), we found that this ADH1B variant was protective
for early drinking milestones, but under the high risk environment of best friends drinking, this
genetic protection was eliminated. These findings illustrate the important interplay between
genes and environments in the development of drinking behaviors. This chapter has been
published in the Journal Alcoholism: Clinical and Experimental Research (Olfson et al., 2014).
7

Olfson E, Edenberg HJ, Nurnberger J Jr, Agrawal A, Bucholz KK, Almasy LA, Chorlian
D, Dick DM, Hesselbrock VM, Kramer JR, Kuperman S, Porjesz B, Schuckit MA,
Tischfield JA, Wang JC, Wetherill L, Foroud TM, Rice J, Goate A, Bierut LJ. An
ADH1B variant and peer drinking in progression to adolescent drinking milestones:
Evidence of a gene-by-environment interaction. Alcohol Clin Exp Res 2014 Sept 24
NIHMSID#936008

Chapter 4 assesses the role of CYP2A6 metabolism on the development of smoking
behaviors during the critical developmental period of young adulthood. By examining over 1,000
European American young adults enrolled in COGA, we found that the CYP2A6 metabolism
metric was not associated with smoking initiation or the development of daily smoking, but
among daily smokers, decreased metabolism was associated with an increased risk of nicotine
dependence. This finding was replicated in an independent sample of young adult daily smokers
enrolled in the Collaborative Study of Nicotine Dependence. These results demonstrate the
complex role of CYP2A6 variation across different developmental stages of smoking behaviors.
At the time of dissertation defense, this chapter was in preparation for submission.
Olfson E, Bloom J, Bertelsen S, Breslau N, Budde J, Chen LS, Culverhouse R, Chorlian
D, Dick DM, Edenberg HJ, Hatsukami D, Hesselbrovck VM, Kramer JR, Kuperman S,
Porjesz B, Saccone NL, Schuckit MA, Stitzel J, Tischfield JA, Goate A, Bierut LJ.
CYP2A6 metabolism in the development of nicotine dependence in young adults.

Chapter 5 examines whether CHRNA5 coding variants, beyond the well-studied
common rs16969968 variant, contribute to nicotine dependence risk. Next-generation
8

sequencing of approximately 3,000 nicotine dependent cases and controls identified the only
known common variant, 3 low frequency, and 22 rare variants. Our results showed that these
newly identified variants independently contribute to nicotine dependence risk. Replication of
common and low frequency variants using 12 independent studies with exome chip data in over
10,000 heavy and 10,000 light smokers further supported this conclusion. These newly identified
low frequency and rare variants may have important health implications by influencing risk for
smoking-related diseases and response to cessation therapies. At the time of dissertation defense,
this chapter was in preparation for submission.
Olfson E, Saccone NL, Johnson EO, Chen LS, Culverhouse R, Doheny K, Foltz SM, Fox
L, Gogarten SM, Hartz S, Hetrick K, Laurie CC, Marosy B, Amin N, Arnett D, Bartz
TM, Bertelsen S, Borecki IB, Brown MR, Chasman DI, van Duijn CM, Feitosa MF, Fox
ER, Franceschini N, Franco OH, Grove ML, Guo X, Hofman A, Kardia SLR, Morrison
AC, Musani SK, Psaty BM, Rao DC, Reiner AP, Rice K, Ridker PM, Rose LM, Rotter
JI, Schick UM, Schwander K, Uitterlinden AG, Vojinovic D, Wang JC, Ware EB, Wilson
G, Yao J, Zhao W, Breslau N, Hatsukami D, Stitzel J, Rice J, Goate A, Bierut LJ.
Common, low frequency, and rare coding variants in CHRNA5 contribute to nicotine
dependence in European and African Americans.

Overall, this work illustrates that although only a limited number of genes clearly
contribute to substance use, hypothesis-driven analyses can advance our understanding of the
specific mechanisms by which these genes alter substance use behaviors. In particular, these
findings illustrate that incorporating environmental factors, critical developmental periods, and
rare variants may refine associations between robust genes and substance use disorders.
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CHAPTER TWO:
Convergence of GWA and candidate gene studies for alcoholism
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2.1 ABSTRACT

Background: Genome-wide association (GWA) studies have led to a paradigm shift in how
researchers study the genetics underlying disease. Many GWA studies are now publicly available
and can be used to examine whether or not previously proposed candidate genes are supported
by GWA data. This approach is particularly important for the field of alcoholism because the
contribution of many candidate genes remains controversial.

Methods: Using the Human Genome Epidemiology (HuGE) Navigator, we selected candidate
genes for alcoholism that have been frequently examined in scientific articles in the past decade.
Specific candidate loci as well as all the reported SNPs in candidate genes were examined in the
Study of Alcohol Addiction: Genetics and Addiction (SAGE), a GWA study comparing alcohol
dependent and non-dependent subjects.

Results: Several commonly reported candidate loci, including rs1800497 in DRD2, rs698 in
ADH1C, rs1799971 in OPRM1 and rs4680 in COMT, are not replicated in SAGE (p> .05).
Among candidate loci available for analysis, only rs279858 in GABRA2 (p=0.0052, OR=1.16)
demonstrated a modest association. Examination of all SNPs reported in SAGE in over 50
candidate genes revealed no SNPs with large frequency differences between cases and controls
and the lowest p value of any SNP was .0006.

Discussion: We provide evidence that several extensively studied candidate loci do not have a
strong contribution to risk of developing alcohol dependence in European and African Ancestry
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populations. Due to lack of coverage, we were unable to rule out the contribution of other
variants and these genes and particular loci warrant further investigation. Our analysis
demonstrates that publicly available GWA results can be used to better understand which if any
of previously proposed candidate genes contribute to disease. Furthermore, we illustrate how
examining the convergence of candidate gene and GWA studies can help elucidate the genetic
architecture of alcoholism and more generally complex diseases.
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2.2 INTRODUCTION

Genome-wide association (GWA) studies have revolutionized the search for common
genetic variants that influence individual risk for complex diseases. Before this revolution, the
discovery of genetic associations was dominated by candidate gene studies that used targeted
gene approaches. Examination of these previous gene association studies demonstrates that most
reported associations are not consistently replicated (Hirschhorn et al., 2002) and the strength of
genetic associations in initial studies commonly erodes in subsequent research (Ioannidis et al.,
2001). Despite this suggested irreproducibility, many candidate gene association studies continue
to be published annually (Yu et al., 2008).
GWA studies rapidly evaluate millions of single nucleotide polymorphisms (SNPs)
throughout the genome and therefore have the potential for identifying key variants in complex
diseases. Since the publication of the first GWA study in 2005 (Klein et al., 2005), over 1000
GWA studies have established genetic associations of more than 200 traits, many of which are
complex diseases. SNP-trait associations from published GWA studies are readily available to
investigators through “A Catalog of Genome-Wide Association Studies” by the National Human
Genome Research Institute (www.genome.gov/gwastudies). More recently, several datasets
from GWA studies have also become available to the scientific community through the database
of Genotypes and Phenotypes (dbGaP) maintained by NCBI (Mailman et al., 2007). These
online scientific databases provide opportunities for investigators to access GWA data.
Online databases can specifically be used to evaluate whether genes that were previously
suggested in candidate gene studies are replicated in GWA studies. Research by Siontis et al.
demonstrates that only a few of previously proposed candidate loci of common diseases reached
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genome-wide significance in GWA studies (Siontis et al., 2010). The loci that did replicate,
however, had important genetic effects and included variants implicated in Alzheimer’s disease
and statin-induced myopathy. Similarly, a recent analysis by Obeidat et al. examined genetic
associations with lung function measures to evaluate the role of previously associated genes in a
large GWA study and clarified the role of many controversial associations (Obeidat et al., 2011).
This approach of comparing candidate gene and GWA studies is powerful because it highlights
which findings have consistent scientific evidence and therefore merit being pursued in future
studies. These findings prompted us to examine whether proposed candidate genes associated
with alcohol dependence are supported by GWA data.
Genetic and environmental factors contribute to individual susceptibility to alcohol
dependence. Twin studies estimate that heritable influences explain 47-64% of variance in risk
for alcohol dependence (Heath et al., 1997; Knopik et al., 2004). Several past research efforts
have focused on targeted gene approaches to shed light on the genes that underlie these heritable
influences. This has led to the proposal of hundreds of candidate genes that contribute to the
development of alcohol dependence (Yu et al., 2008). A few GWA studies have also explored
genes potentially involved in alcohol dependence (Bierut et al., 2010; Edenberg et al., 2010;
Farrer et al., 2009; Heath et al., 2011; Hodgkinson et al., 2010; Joslyn et al., 2010; Treutlein et
al., 2009; Zlojutro et al., 2011). Despite extensive candidate gene studies and several GWA
studies, little consensus exists over which if any genes contribute to the genetic basis of alcohol
dependence.
The existence of many controversial candidate genes for alcoholism highlights the need
for further research on whether or not these genes replicate in large datasets. Results from the
Study of Alcohol Addiction: Genetics and Addiction (SAGE) have recently become available
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through dbGaP. SAGE compares DSM-IV alcohol dependent individuals and non-dependent,
unrelated control subjects of European and African American descent. Using the SAGE data, we
examined differences in SNP frequencies between cases and controls within previously reported
candidate genes. These targeted candidate genes were selected using the Human Genome
Epidemiology (HuGE) Navigator, a publicly searchable database established in 2001 of
published genetic association and human genome epidemiological studies (Yu et al., 2008). The
HuGE Navigator along with the SAGE results facilitated the systematic examination of
candidate genes considered in many alcoholism studies over the last decade.
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2.3 MATERIALS AND METHODS

Selection of Candidate Genes
The HuGE Navigator was developed using PubMed abstracts as the core data source and
using data and text mining algorithms to develop a knowledge database (Yu et al., 2008). Each
week since 2001, articles are systematically deposited in the database and represent a
comprehensive list of recent articles. An automatic literature program screens PubMed for
abstracts and then a genetic epidemiologist selects abstracts meeting inclusion criteria and
indexes them. Phenopedia of the HuGE Navigator gives a disease-centered view of genetic
association studies by providing information about genes studied in relation to a queried
phenotype (Yu et al., 2010). Phenopedia was queried in July 2011 for Alcoholism and 584 genes
were retrieved.
We focused our study on genes that have been frequently characterized by candidate gene
studies. In primary analysis, over 90% of the genes associated with alcoholism in the HuGE
database have 5 or fewer publications (528 out of 584 genes). The 56 candidate genes that have
more than 5 publications vary substantially in the number of publications (6-103 publications).
Figure 2.1A highlights that many genes have one or a few reported publications and there are
some outliers that have been examined in many papers. This distribution may be explained in
part by the fact that many of the genes with a low number of publications have been primarily
identified in a GWA study and are not well characterized in targeted candidate gene studies.
Figure 2.1B demonstrates that for almost 50% (176/386) of the genes with one publication that
publication is itself a GWA study. Based on these preliminary observations, we narrowed our
investigation to genes with more than 5 publications to focus our analysis on well-studied genes.
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Since the X chromosome is not included in the publicly available SAGE results, the two
candidate genes on the X chromosome MAOA and HTR2C, which have 26 and 8 publications
respectively, were excluded from the analysis. The 54 autosomal genes that had more than 5
publications were pursued using the SAGE dataset. For the remainder of this paper, we will only
refer to the 54 autosomal candidate genes.

SAGE Data
SAGE is a case-control study that analyzed genetic data on over 3,800 phenotyped
subjects funded as part of the Gene Environment Association Studies (GENEVA) initiative
supported by the National Human Genome Research Institute (Bierut et al., 2010). Alcoholdependent cases and controls were selected from three large datasets: the Collaborative Study on
the Genetic of Alcoholism (COGA), the Family Study of Cocaine dependence (FSCD) and the
Collaborative Genetic Study of Nicotine Dependence (COGEND). Cases are required to have a
lifetime history of DSM-IV alcohol dependence. Controls are required to have been exposed to
alcohol because alcohol use is necessary to develop dependence, but not to have met lifetime
diagnosis criteria for alcohol dependence or dependence for illicit drugs. A common assessment
was performed for all cases and controls in the three studies that was based on the SemiStructured Assessment for the Genetics of Alcoholism (SSAGA) (Bucholz et al., 1994). The
common methodology of interview administration, question format and queried domains enabled
phenotypic standardization across the three studies (Bierut et al., 2010). Characteristics of the
cases and controls in the SAGE dataset are listed in Table 2.1 and additional information is
available at http://www.ncbi.nlm.nih.gov/projects/gap/cgi-
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bin/study.cgi?study_id=phs000092.v1.p1. The SAGE dataset is publicly searchable through the
Genome Brower under the Analysis tab on this website.
The power Calculator for Association with Two Stage design (CATS) was used to
determine what effect sizes the SAGE dataset is able to detect (Skol et al., 2006). Using a sample
size of 1900 cases and 1900 controls and an alpha level of .05, we calculated different allele
frequencies and risk ratios.

Examination of SNPs in Candidate Genes
The HuGE database was used to survey articles on the ten candidate genes that had the
most publications (listed in Table 2.2). The most well established loci based on expert opinion of
the literature for each of the top ten candidate genes was searched in the genome browser to test
whether candidate loci that had been highly reported in candidate gene studies replicated in the
SAGE dataset. Since allele A9 for SLC6A3 is a VNTR, we examined the two SNPs rs27072 and
rs27048 as proxies because they have been found to be associated with similar withdrawal
symptoms and are roughly in the same region of the gene as the VNTR (Le Strat et al., 2008). As
the originators of the SAGE dataset, we were also able to compare the odds ratios and p values
within the original three datasets (COGA, FSCD and COGEND) to verify whether there was any
heterogeneity across the three contributing studies.
The 54 candidate genes with more than 5 publications were identified and chromosomal
regions containing the gene plus 10 kb both 5’ and 3’ of the gene were examined. These
expanded regions were searched using the SAGE genome browser and SNPs within these
regions with p<.05 were recorded.
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For each candidate gene, all SNPs with p<.05 were queried together in SNP Annotation
and Proxy Search (SNAP) to assess linkage disequilibrium (Johnson et al., 2008). These searches
were performed using the 1000 genomes pilot 1 SNP dataset, an r2 > .8, and a distance limit of
500. This analysis was performed with both the CEU and YPI population panels separately
because of allele frequency differences between European American and African American
subsets. All SNPs that had an r2 greater than 0.8 and at least one other variant in a group were
considered a cluster.
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2.4 RESULTS

The SAGE dataset contains half of the most commonly reported variants associated with
the ten most well studied candidate genes (Table 2.2). Of the 5 candidate variants reported in
SAGE, the only variant with a p< .05 is rs279858 in GABRA2 (p=.0052, OR=1.16). The
commonly reported variants, rs1800497 in DRD2, rs698 in ADH1C, rs1799971 in OPRM1 and
rs4680 in COMT, have p> .05. The minor allele for rs17999971 in OPRM1 trends towards being
protective (OR=.88) while the minor alleles of rs1800497 in DRD2, rs698 in ADH1C and rs4680
in COMT trend toward being associated with alcohol dependence (OR=1.11,1.08,1.02
respectively). The effects of these associations are in the expected direction based on previous
candidate gene studies (Blum et al., 1990; Bond et al., 1998; Hendershot et al., 2011; Ponce et
al., 2008; Thomasson et al., 1991; Tiihonen et al., 1999; Tolstrup et al., 2008; Zhang et al.,
2006). In addition, these effects in SAGE were similar to the findings in the individual three
studies that contributed to SAGE: COGA, FSCD and COGEND. Across the three contributing
studies, the odds ratios ranged from 1.07-1.13 for rs1800497 in DRD2, 1.06-1.11 for rs698 in
ADH1C, 0.82-0.95 for rs1799971 in OPRM1, 1.09-1.17 for rs279858 in GABRA2 and 1.02-1.09
for rs4680 in COMT (data not shown).
Several commonly reported variants associated with alcoholism are not on the Illumina
chip that was used to generate the SAGE dataset. These SNPs include rs671 in ALDH2,
rs1229984 in ADH1B, rs4795541 in SLC6A4 and rs3813867 in CYP2E1. Since the A9 allele in
SLC6A3 is a VNTR and therefore also not reported in SAGE, we examined two proxy SNPs (Le
Strat et al., 2008). Neither of these two SNPs show a significant difference between the cases and
controls (p=.8646 for rs27072 and p=.3842 for rs27048).
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In every gene with more than 5 publications, few SNPs had impressive differences
between cases and controls. Of the 2175 SNPs reported in the 54 genes with more than 5
publications, approximately 5% have a p<.05 (116/2175) and approximately 1% have a p<.01
(16/2175) (Table 2.3). The lowest p value of any variant was 0.0006 for rs925946, which is a
SNP upstream of BDNF.
In a few genes, a large proportion of the SNPs have modest frequency differences
between cases and controls. In 10 out of the 54 genes examined, more than 10% of the SNPs
have p<.05 and in 3 genes this portion exceeds 20%. Specifically, the proportion of SNPs in
SAGE with p<.05 is 55% (16/29) in GABRA2, 24% (10/29) in BDNF and 44% (4/9) in HTR1A
(Table 2.3). To test whether the large proportion of SNPs with small p values in these genes
could be explained by linkage disequilibrium, we performed SNAP analyses.
Many variants clustered as defined by r2> 0.8 within the genes but the proportion of
clusters containing SNPs with p<.05 remained quite similar with SNAP analyses in both CEU
and YPI populations (data not shown). Of the variants with linkage disequilibrium data available
in SNAP for the CEU population, 27 SNPs in GABRA2 broke down into 10 clusters of which 5
clusters had SNPs with p<.05 (50%), 24 SNPs in BDNF broke down into 9 clusters of which 4
clusters had SNPs with p<.05 (44%), and 6 SNPs in HTR1A broke down into 3 clusters of which
1 cluster had SNPs with p<.05 (33%). Generally fewer SNPs clustered in the YRI population
than in the CEU population but the proportion of clusters containing SNPs with p<.05 was
comparable between the two populations. In the YRI population, 25 SNPs in GABRA2 broke
down into 16 clusters of which 12 clusters had SNPs with p<.05 (75%), 25 SNPs in BDNF broke
down into 19 clusters of which 10 clusters had SNPs with p<.05 (53%), and 9 SNPs in HTR1A
broke down into 5 clusters of which 2 cluster had SNPs with p<.05 (40%).
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Power calculations demonstrate that the SAGE dataset has 90% power with an alpha
level of .05 to detect a genetic variant with a minor allele frequency of .10 and an odds ratio of
1.25 or greater. The dataset also has 90% power with an alpha level of .05 to detect a variant
with a minor allele frequency of .40 and an odds ratio of 1.15 or greater.
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2.5 DISCUSSION

Over the last decade, hundreds of candidate genes have been proposed for alcoholism.
We used local and global approaches to specifically investigate variants within the most widely
studied of previously proposed candidate genes. Our primary finding is that most of these
candidate genes are not strongly supported by GWA data. This observation reduces the
likelihood that these previously proposed genes individually have a strong effect on the genetic
risk of alcohol dependence. The results mirror prior work that most candidate loci in common
diseases are not strongly replicated in GWA studies except for a few biologically important
variants (Siontis et al., 2010; Obeidat et al., 2011).
Analysis of well-characterized loci that were previously proposed in candidate gene
studies in a large GWA study on alcoholism, SAGE, reveals unimpressive differences between
cases and controls at most loci. The frequently studied variants associated with alcoholism in
DRD2, ADH1C, OPRM1 and COMT demonstrate insignificant frequency differences in SAGE
(p>.05, Table 2.2). Although several studies implicate a biological role of these variants in
alcoholism (Blum et al., 1990; Bond et al., 1998; Hendershot et al., 2011; Ponce et al., 2008;
Thomasson et al., 1991; Tiihonen et al., 1999; Tolstrup et al., 2008; Zhang et al., 2006), our
results reveal that these variants are not strongly associated with alcoholism in European and
African ancestry populations. The only candidate that modestly replicated in SAGE, rs279858 in
GABRA2, had a p-value of 0.0052 (OR=1.572). This finding was anticipated because a previous
GWA study on the SAGE dataset demonstrated a similar association (Bierut et al., 2010). The
replication of rs279858 in SAGE provides some support for future studies focused on the
function of this variant and associated variants in GABRA2 (Edenberg et al., 2004).
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When examined globally, none of the well-studied candidate genes demonstrate
impressive variant differences between cases and controls. More specifically, only one SNP
reported in SAGE (rs925946 upstream of BDNF, p=0.0006) in the 54 candidate genes had a p
value less than 0.0009, a corrected p value for the number of genes (.05/54= 0.0009).
Additionally, the overall number of variants with p<.05 and p<.01 is close to that predicted by
chance considering the total number of SNPs examined in all proposed candidate genes.
Although the individual p values for variants in the examined candidate genes are modest, a few
candidate genes have a large portion of SNPs with p<.05 (Table 2.3). The results support further
research into whether GABRA2, which was the candidate gene with the largest proportion of
SNPs with p< .05 (55%), contributes to risk of developing alcohol dependence. BDNF and
HTR1A also had more than one fifth of SNPs with p<.05, indicating that these genes merit
further investigation to elucidate their potential contribution to alcohol dependence.
Lack of replication in SAGE does not exclude the possibility that some previously
proposed candidate genes and specific loci are biologically important. Several of the most well
studied candidate loci for alcoholism were not available in SAGE, including rs671 in ALDH2,
rs1229984 in ADH1B, rs4795541 in SLC6A4 and rs3813867 in CYP2E1. A recent study that
specifically genotyped rs1229984 in SAGE reported that the minor allele has a significant
protective effect on alcohol dependence ( p=6.6x 10-10) (Bierut et al., 2011). Because rs1229984
is common in Asians but rare in European Americans, this variant in ADH1B was not genotyped
in the original GWA study. This highlights that GWA studies may miss important variants
because of lack of coverage of SNPs that are uncommon in European American populations.
Additionally, GWA studies cannot assess all forms of inheritance that can be associated with
candidate genes such as insertion/deletion mutations, copy number repeats and epigenetic
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changes. Although SAGE is a valuable tool, it cannot exclude the possibility that aspects of
genes contribute to genetic risk of alcohol dependence.
Even though the well studied candidate variants in DRD2, ADH1C, OPRM1 and COMT
were not significantly associated with alcohol dependence in SAGE, their odds ratios were in the
expected direction based on previous candidate gene studies. More specifically, the odds ratio of
0.088 for rs1799971 in OPRM1 supports previous studies that the minor allele variant is
protective against alcohol dependence (Bond et al., 1998; Zhang et al., 2006) while the odds
ratios greater than 1 for rs1800497 in DRD2, rs698 in ADH1C, and rs4680 in COMT supports
previous studies that the minor allele of these variants are more common in alcohol dependent
individuals (Blum et al., 1990; Hendershot et al., 2011; Ponce et al., 2008; Thomasson et al.,
1991; Tiihonen et al., 1999; Tolstrup et al., 2008). The fact that these odds ratios are in the
expected direction but did not pass a threshold of .05 for significance may suggest that these
variants have a small contribution to alcohol dependence and this study lacked the power to
detect the association.
Our study design had several strengths. First, the literature search for candidate genes
included all genetic associations irrespective of ethnicity and criteria for alcoholism. By
including all genes with the most genetic association study publications, we comprehensively
examined previously identified genes associated with alcoholism in a large GWA study on
alcoholism. Second, the SAGE dataset has the power to detect associations of small magnitude.
SAGE included more than 3,800 subjects and had 90% power to detect a genetic variant with an
odds ratio of 1.25 for a risk locus with 10% minor allele frequency. Third, our findings in SAGE
regarding the well-characterized loci were found to be very similar to the results in the three
independent datasets that contributed to SAGE, which indicates that there is no heterogeneity
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across these datasets. Fourth, our approach used data that is available to the scientific community
and can be easily replicated in future studies of other phenotypes.
Despite these strengths, the selection of candidate loci and genes based on number of
publications retrieved by the HuGE Navigator Phenopedia has some limitations. One limitation
is that no data suggests that the potential significance of a given gene is directly proportional to
the number of publications. Despite this, we felt that the number of publications is an indicator of
research efforts devoted to a given gene. By selecting genes with the most publications, we
sought to capture well-studied genes that had been the focus of the field in the past. A second
potential limitation is that we did not exclude publications based on the same datasets. Because
we used a low threshold of greater than 5 publications in the initial analysis, however, we are
confident that we did not exclude any genes that have been examined in many studies.
Additionally, the most well-studied loci of the ten genes with the most publications were selected
based on expert opinion and were felt to be unambiguously widely studied even if the exact order
may not be reflective of the number of data sets published on the genes.
Beyond limitations in our selection of candidate genes, the SAGE dataset has limitations
that restrict the interpretation of our results. First, some of the most well studied variants were
not covered in SAGE and therefore could not be assessed. Second, the X chromosome is not
included in the publically available SAGE results so we were unable to investigate genes on the
X chromosome. Specifically, two candidate genes on the X chromosome, MAOA and HTR2C
that had 26 and 8 publications respectively, were not assessed. Third, SAGE is limited in its
power to identify genotyped variants on the GWA chip that have small effect sizes. Despite the
fact that the SAGE dataset was relatively large when it was originally published, identifying
common variants with small effect sizes (<1.1) remains challenging and we are unable to rule out
35

the possibility of real but modest effects of these genes. Forth, variants that are uncommon (1%5%) or rare (<1%) in the study population may also not be detected in SAGE because of their
individually small contribution to overall alcoholism. Fifth, the SAGE dataset primarily consists
of European Americans (69.5%), African Americans (30.3%) and a few Hispanics (3.4%) (Table
2.1) and association findings may be different in other populations such as Asians. Some of the
genes and variants examined in this analysis are more well studied and have a higher frequency
in Asian Ancestry than in European and African Ancestry populations, such as the Asp40 allele
of the candidate variant rs1799971 in OPRM1 (Arias et al., 2006), and therefore may have a
more impressive effect in studies that focus on Asian ancestry populations. Sixth, our analysis
did not examine the effects of combinations of genes or the effect of different environmental
factors. Analysis of multiple genes and populations enriched for specific environmental risk
factors will likely explain a greater degree of the genetic risk of alcoholism. Despite these
limitations, this analysis demonstrates that GWA studies are a powerful technique for verifying
the importance of genes and particular variants that have been previously identified in the
candidate gene era.
In summary, we provide evidence that for alcohol dependence, several extensively
studied candidate loci and genes are not replicated in a large GWA study, indicating that these
variants do not individually have a large contribution to risk of developing alcohol dependence in
European and African ancestry populations. Our analysis was unable to rule out the possibility
that some variants and genes are important for risk of alcoholism due to lack of coverage. Recent
work demonstrates that at least one highly reported variant rs1229984 in ADH1B that is not
reported in SAGE is significantly associated with alcoholism (Bierut et al., 2011), suggesting the
possible importance of further research on highly supported variants that cannot be assessed in
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SAGE. Our approach may also have missed variants that have a real but small individual
contribution to overall inheritance of alcoholism.
This analysis demonstrates that targeted candidate gene studies and GWA studies each
provide important information and studying the convergence of these two experimental designs
has the potential to advance understanding of the etiology of alcohol dependence and more
generally complex diseases. While GWA studies provide important information about the
genetic contribution of common variants to complex diseases across populations, hypothesis
driven candidate gene studies are also important to assess variants of lesser significance that may
be missed because of the strict p value thresholds required for the large number of comparisons
in GWA studies. Incorporating knowledge from both GWA and candidate gene studies will help
clarify the role of genetics in complex disease and guide future research.
Our study also shows how the HuGE Navigator and dbGaP databases can be used as
tools by researchers to easily access and analyze information on candidate genes and GWA data.
Beyond alcoholism, the HuGE Navigator provides an easy way for investigators to search over
2,000 diseases and 10,000 genes for summary information and primary articles about genetic
associations and human genome epidemiology (Yu et al., 2008). The dbGaP database provides
access to results of over 100 studies examining phenotype and genotype associations, including
40 GWAS studies on different diseases. Since dbGaP currently contains a limited number of
GWA studies, researchers examining phenotypes not available in dbGaP may benefit from
directly contacting the authors of relevant GWA studies and meta analysis. Because of this easy
accessibility, researchers who intend to perform future candidate gene studies should reference
the HuGE navigator to assess background information and use dbGaP and existing GWA data to
test whether their gene of interest is replicated in GWA data. Candidate gene studies need
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replication to meet scientific standards. Simple dbGaP analyses may help to focus future research
on genes that are supported by GWA data and therefore more likely to be biologically important
for human disease.
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2.8 TABLES
Table 2.1. Characteristics of alcohol dependent cases and non-dependent controls in SAGE
Characteristic
Sex, n (%)
Males
Females
Age, years
Mean + SD
Range
Self-reported race, n (%)
European-American
African-American
Self-reported ethnicity, n (%)
Hispanic
Alcohol dependence
Diagnosis, n (%)

Cases n=1,897

Controls n=1,932

Total n=3,829

1.155 (60.9)
742 (39.1)

606 (31.4)*
1,326 (68.6)

1,761 (46.0)
2,068 (54.0)

39.0 + 9.3
18.0-77.0

39.3 + 9.1
18.0-65.0

19.2 + 9.2
18.0-77.0

1,235 (65.1)
662 (34.9)

1,433 (74.2)*
499 (25.8)

2,668 (69.5)
1,161 (30.3)

76 (4.0)

56 (2.8)

132 (3.4)

1,897 (100.0)

0 (0.0)*

1,897 (49.5)

Sex, age, race, ethnicity and alcohol dependence characteristics of cases and controls in the
Study of Alcohol Addiction: Genetics and Addiction (SAGE) dataset (Bierut et al., 2010).
* p<0.0001 for difference between cases and controls
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Table 2.2. Examination of Top Ten Candidate Loci for Alcoholism in SAGE
Candidate
Genes

Publications on
Alcoholism
association

Commonly
reported SNP

ALDH2

103

rs671

ADH1B

89

DRD2

Common Name of SNP

P value in
SAGE

Odds Ratio in
SAGE (CI)

ALDH2*2
(Harada, 1982)

-

-

rs1229984

ADH1B*2/ADH2*2
(Thomasson, 1992)

-

-

83

rs1800497

TaqIA
(Blum, 1990)

0.09

1.1053 (.9845-1.2408)

SLC6A4

83

rs4795541

5-HTTLPR/S allele
(Sander, 1997)

-

-

ADH1C

51

rs698

ADH1C*2
(Thomasson, 1992)

0.1452

1.0819 (.9732-1.2028)

OPRM1

38

rs1799971

Ala118Gly
(Bond, 1998)

0.1372

.8823 (.7481-1.0407)

CYP2E1

35

rs3813867

CYPE1*c2
(Hayashi, 1991)

-

-

GABRA2

27

rs279858*

(Edenberg, 2004)

0.0052

1.1572 (1.0445-1.2821)

COMT

26

rs4680

Val158Met
(Tiihonen, 1999)

0.6328

1.0244 (.9278-1.1311)

SLC6A3

25

**

A9 (VNTR)
(Dobashi, 1997)

In the ten most frequently studied genes associated with alcoholism according to the Human
Genome Epidemiology (HuGE) Navigator, the most well studied variants were examined in
Study of Alcohol Addiction: Genetics and Addiction (SAGE).
*One of over 20 SNPs significantly associated with alcohol dependence (Edenberg et al., 2004).
This SNP was examined because it was the only one in an exon.
**Examined 2 SNPs, rs27072 and rs27048, as proxies (Le Strat et al., 2008)

47

Table 2.3. SNPs in frequently studied candidate genes associated with Alcoholism
Candidate
Genes
ALDH2
ADH1B
DRD2
SLC6A4
ADH1C
OPRM1
CYP2E1
GABRA2
COMT
SLC6A3
HTR2A
HTR1B
DRD4
BDNF
NPY
DRD3
APOE
MTHFR
GABRA6
TPH1
GRIN2B
CNR1
TPH2
ADH4
CHRM2
CRHR1
ANKK1
ALDH1A1
DRD1
GABRG2
GABRB2
HTR1A
GSTM1
OPRD1
OPRK1
GABRB3
GABRA1
DBH
ADH1A
ADH5
GAD1
HFE
GRIN1
GAD2
GABRB1
ADH7
ADRA2A
CHRNA5
POMC
SLC6A2
CCKBR
CCKAR
TNF
CCK
Total (n=54)

Publications on
Alcoholism

SNPs recorded
in dbSNP

Total SNPs in
SAGE

p<.05

p<.01

p<.005

p<.001

103
89
83
83
51
38
35
27
26
25
22
18
18
16
15
14
13
13
13
13
12
12
11
10
10
9
9
9
9
9
9
9
9
9
9
8
8
8
8
7
7
7
6
6
6
6
6
6
6
6
6
6
6
6

407
337
826
637
522
3568
210
1692
752
1322
1036
60
184
624
241
693
106
324
215
277
5233
2778
1415
830
1992
1183
218
739
82
991
2699
45
123
585
226
23
583
562
293
584
692
188
513
784
4354
288
46
254
102
837
300
167
177
461

24
21
41
21
29
122
49
29
55
38
61
12
9
29
19
31
12
49
18
14
245
27
54
62
62
26
26
122
19
30
80
9
3
20
37
104
20
47
19
38
31
28
18
49
111
32
9
16
10
49
20
15
36
18
2175

7
2
1
4
16
8
2
10
2
3
1
11
5
1
1
3
1
4
3
1
4
1
9
1
2
1
1
1
2
1
4
2
1
116

1
5
1
2
4
2
1
16

1
2
3
6

1
1
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SNPs in SAGE

All genes with more than 5 publications in Human Genome Epidemiology (HuGE) Navigator
were examined in Study of Alcohol Addiction: Genetics and Addiction (SAGE). Genes were
expanded by 10 kb on both sides before they were queried in the SAGE database. MAOA and
HTR2C were excluded because they were on the X chromosome.
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2.9 FIGURES

Figure 2.1. Characteristics of genes associated with Alcoholism in the Human Genome
Epidemiology (HuGE) Navigator (A) Distribution of number of publications on genes; (B)
Proportion of genes observed in at least one GWA study stratified based on number of
publications. 4 genes were identified in 2 GWA study (these genes had 2, 2, 10 and 51
publications). All other genes were found in 1 or none GWA study. A total of 8 GWA studies on
Alcoholism are listed in the HuGE database (Bierut et al., 2010; Edenberg et al., 2010; Farrer et
al., 2009; Heath et al., 2011; Hodgkinson et al., 2010; Joslyn et al., 2010; Treutlein et al., 2009;
Zlojutro et al., 2011).
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CHAPTER THREE:
An ADH1B variant and peer drinking in progression to adolescent drinking milestones:
Evidence of a gene-by-environment interaction
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3.1 ABSTRACT

Background: Adolescent drinking is an important public health concern, one that is influenced
by both genetic and environmental factors. The functional variant rs1229984 in alcohol
dehydrogenase 1B (ADH1B) has been associated at a genome-wide level with alcohol use
disorders in diverse adult populations. However, few data are available regarding whether this
variant influences early drinking behaviors and whether social context moderates this effect. This
study examines the interplay between rs1229984 and peer drinking in the development of
adolescent drinking milestones.

Methods: 1,550 European and African American individuals who had a full drink of alcohol
before age 18 were selected from a longitudinal study of youth as part of the Collaborative Study
on the Genetics of Alcoholism (COGA). Cox proportional hazards regression, with GxE product
terms in the final models, was used to study two primary outcomes during adolescence: age of
first intoxication and age of first DSM-5 alcohol use disorder symptom.

Results: The minor A allele of rs1229984 was associated with a protective effect for first
intoxication (HR=0.56, 95% CI 0.41-0.76) and first DSM-5 symptom (HR=0.45, 95% CI 0.260.77) in the final models. Reporting that most or all best friends drink was associated with a
hazardous effect for first intoxication (HR=1.81, 95% CI 1.62-2.01) and first DSM-5 symptom
(HR=2.17, 95% 1.88-2.50) in the final models. Furthermore, there was a significant GxE
interaction for first intoxication (p=.002) and first DSM-5 symptom (p=.01). Among individuals
reporting none or few best friends drinking, the ADH1B variant had a protective effect for
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adolescent drinking milestones, but for those reporting most or all best friends drinking, this
effect was greatly reduced.

Conclusions: Our results suggest that the risk factor of best friends drinking attenuates the
protective effect of a well-established ADH1B variant for two adolescent drinking behaviors.
These findings illustrate the interplay between genetic and environmental factors in the
development of drinking milestones during adolescence.
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3.2 INTRODUCTION

By age 17, most U.S. adolescents (54%-78%) have consumed alcohol, and a significant
proportion (15%) meet the criteria for alcohol abuse (Merikangas et al., 2010; NSDUH, 2012;
Swendsen et al., 2012). Patterns of alcohol use that begin in adolescence are important
determinants for the development of alcohol use disorders during adulthood (Grant et al., 2006;
Pitkanen et al., 2005). Therefore, understanding factors that contribute to early drinking
behaviors is critical for disease prevention.
For decades, twin studies have recognized that both genetic and environmental factors
influence individual risk for alcoholism (Heath et al., 1997; Kendler et al., 1994; Pickens et al.,
1991; Prescott and Kendler, 1999). Recently, large-scale genetic studies have provided strong
evidence for the contribution of specific genetic variants to alcohol use disorders in adults
(Rietschel and Treutlein, 2013; Wang et al., 2012). An important next step in the translation of
genetic findings identified in adults is to test whether these genetic variants also affect adolescent
drinking behaviors and whether environmental risk factors moderate this role.
Among the most biologically well-understood genetic variants associated with alcohol
use disorders is the polymorphism rs1229984 in the enzyme alcohol dehydrogenase 1B
(ADH1B). The minor A allele (in the coding strand) of rs1229984 causes an amino acid change
at position 48 by replacing arginine with histidine, which increases the activity of the ADH1B
enzyme that oxidizes ethanol to acetaldehyde (Edenberg and Foroud, 2013; Hurley and
Edenberg, 2012). After consuming alcohol, elevated ADH1B activity has been hypothesized to
transiently increase the level of acetaldehyde, leading to unpleasant effects that limit further
drinking. Meta-analysis of this variant in Asian populations, where the rs1229984 A allele is
54

common (allele frequency=0.7 in 1000 Genomes)(Abecasis et al., 2012), has demonstrated
strong effects on the risk of developing alcohol-related disorders (OR 0.45: p=7x10-42) (Li et al.,
2011). Recently, this polymorphism was shown to have a similar effect on risk of alcohol
dependence in European and African Americans (African and European OR 0.34: p=6.6x10-10
(Bierut et al., 2012); European: p=1.17x10-31(Gelernter et al., 2014)), where the rs1229984 A
allele is less common (European American frequency=0.05; African American frequency=0.02
in Exome Variant Server)(http://evs.gs.washington.edu/EVS/).
Other studies suggest that social environments that encourage drinking may diminish the
protective genetic effects of alcohol metabolizing variants (Hasin et al., 2002; Higuchi et al.,
1994; Irons et al., 2007; Irons et al., 2012). However, to our knowledge, no study has explored
the interplay of the ADH1B rs1229984 variant and the important social context of peer drinking
during the critical developmental period of adolescence when alcohol use is initiated and
drinking patterns are established. Peer drinking has long been recognized as a strong risk factor
for adolescent drinking problems (Curran et al., 1997; Reifman et al., 1998), and recently, twin
studies have provided evidence that peer drinking modifies heritable variation in adolescent
alcohol involvement (Agrawal et al., 2010; Dick et al., 2007; Guo et al., 2009; Harden et al.,
2008).
This study tests the interaction between a genome-wide significant functional ADH1B
variant and the risk environment of peer drinking in the development of two adolescent drinking
milestones: first intoxication and first DSM-5 alcohol use disorder symptom. Examining
hypothesis-driven gene-by-environment (GxE) interactions using robust genetic and
environmental risks during developmental transitions provides an important approach for
untangling the complex etiology of alcohol use disorder.
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3.3 MATERIALS AND METHODS

COGA Sample Description
Study participants were enrolled in the Collaborative Study on the Genetics of
Alcoholism (COGA), a large, multi-center, family study designed to identify genes that
contribute to alcohol use disorders in high-risk (defined as recruited through alcohol dependent
probands) and community comparison families (Begleiter et al., 1995). Since 2005, the
adolescent and young adult study in COGA has used a longitudinal design to examine the
development of alcohol use disorders in young participants from these families. Individuals aged
12 to 22 were recruited from six sites across the US and interviewed every two years.
Institutional review boards at all sites approved the study design. Adult participants provided
informed consent, parents provided consent for all children younger than 18, and children
provided assent.

Assessment of Phenotypes
Interview assessment was performed using the Semi-Structured Assessment for the
Genetics of Alcoholism (SSAGA) to gather reliable and valid information on alcohol use
behaviors (Bucholz et al., 1995; Bucholz et al., 1994; Hesselbrock et al., 1999). Participants 18
years and older were assessed with the Phase IV SSAGA, and those less than 18 years were
assessed with an age appropriate adolescent version called the Phase IV C-SSAGA (Kuperman
et al., 2001).
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Drinking Milestones
Two adolescent drinking milestones were used as primary outcomes among adolescent
ever-drinkers: age of first intoxication, a common and clinically relevant variable, and first
DSM-5 alcohol use disorder symptom, a heritable characteristic associated with future alcoholrelated problems (Rhee et al., 2003; Young et al., 2006). These outcomes commonly occur
during adolescence and therefore coincide with the environment of adolescent peer drinking.
Age of first intoxication was derived from responses to the question “How old were you the first
time you got drunk, that is, your speech was slurred or you were unsteady on your feet?” Age of
first DSM-5 symptom was developed from examining the youngest age that individuals first
experienced one of the 11 symptoms of alcohol use disorder. Given the longitudinal design of
this study with multiple assessments over time, the earliest interview in which the participant
endorsed first intoxication or first DSM-5 symptom was selected to assign the age of onset.

Peer Drinking
The environment of adolescent peer drinking was derived from participant responses to
questions addressing the proportion of best friends who drink. With the longitudinal design of
the study, 88% (1366/1550) of participants received at least one adult SSAGA assessment at age
18 years or older. Assignment of the level of peer drinking in these participants was determined
from the first adult SSAGA interview with the question “When you were 12-17, how many of
your best friends used alcohol?” and the 4 possible answers of none, few, most, or all. For
participants who had not reached age 18 at the last assessment, peer drinking was evaluated with
the maximum value from all C-SSAGA answers to the question “How many of your best friends
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use alcohol?” For the primary analyses, peer drinking was dichotomized into low peer drinking
(few or no best friends drink) and high peer drinking (most or all best friends drink) as done in
previous studies (Kuperman et al., 2013). The four level peer drinking variable (none, few, most,
or all best friends) was also investigated in secondary analyses to assess a possible dose
response, but interaction effects are not presented because of the small number of individuals in
some groups.
To assess the concordance of the retrospective SSAGA interview peer drinking responses
for ages 12-17 with current peer drinking reported in C-SSAGA assessments, we compared the
first adult SSAGA response and the maximum value from all C-SSAGA assessments among
individuals with at least one adult and one child questionnaire. For the 996 participants with both
adult and child interviews, 73% of peer drinking assignments had the same dichotomous variable
(none/few vs most/all best friends). This concordance demonstrates that our retrospective
approach of using the first SSAGA interview when available is a reasonable strategy to assess
peer drinking across adolescence. It also shows that for the 12% of participants without a single
adult SSAGA assessment, using the maximum value from C-SSAGA assessments reasonably
estimates the proportion of best friends drinking from ages 12-17.

Genotyping
Blood samples were obtained for genetic analysis. The ADH1B rs1229984 variant was
genotyped with Sequenom MassArray technology (Sequenom, San Diego, CA, USA) following
standard procedures. Several quality control measures were employed. Genetic variants had a
genotyping rate of greater than 99% and were in Hardy-Weinberg equilibrium in both the
European and African American groups. The program PEDCHECK (O'Connell and Weeks,
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1998) was used to examine Mendelian inheritance, and only individuals with no Mendelian
inconsistencies were included in the rs1229984 genotyped sample (N=2580, Figure 3.1).
A set of 64 ancestry informative markers was genotyped as part of a 96 SNP
Biorepository Panel by the Rutgers University Cell and DNA Repository. These markers were
used in SNPrelate, a function in R, to assign ancestry groups. HapMap populations were
included as reference groups. There was high concordance (97%) between self-reported and
genetically determined ethnicity for European and African American individuals, and only
concordant individuals were used in the analyses.

Sample Selection
In the COGA adolescent and young adult study, 2,580 individuals with a first interview
age of 12 to 22 were genotyped for the ADH1B rs1229984 variant, and participants for the
analyses were drawn from this group (Figure 3.1). Focusing on European and African American
subjects and excluding individuals with missing or unreliable data left 2,410 individuals (entire
sample described in Table 3.1). The samples used for the primary analyses of first intoxication
and first DSM-5 symptom consisted of 1,550 ever-drinkers before age 18 (also described in
Table 3.1). Ever-drinkers were targeted because the ADH1B variant is only expected to exhibit
a protective effect in response to alcohol consumption. Because the peer drinking variable
examined the age-range of 12-17, the primary analyses focused on events that occurred during
this time.
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Data Analysis
Data were analyzed using the Statistical Analysis System (SAS 9.3, Cary, NC, USA).
Cox-Proportional Hazards Regression (SAS PROC PHREG) was used to model drinking
milestones and all individuals who did not experience an event in adolescence were censored at
their age of last interview or 18. Participants with rs1229984 GA genotype (N=96) and AA
genotype (N=2) were collapsed into one group for comparison with the GG genotype
participants (N=1,452), as done in previous studies (Bierut et al., 2012). Models were checked
for violations of the proportional hazards assumption and Schoenfeld residuals were examined.
The option COVSANDWICH (AGGREGATE) was used to statistically adjust for the nonindependence of correlated familial data in all analyses, as done in previous studies (Kuperman
et al., 2013).

Models in Primary Analyses
Main effects of the ADH1B variant and peer drinking were examined in univariate and
multivariate models of age of first intoxication and first DSM-5 symptom in the sample of
adolescent ever-drinkers (N=1,550, called univariate model set and multivariate model set,
Table 3.2). All models presented in the tables employed STRATA statements for gender and
ethnicity to adjust for differences in baseline hazards in these groups. The interplay between the
ADH1B variant and peer drinking was assessed by adding product interaction terms to models of
drinking milestones (called interaction model set, Table 3.2). This final proportional hazards
model was λ(t)=λ(t)exp(β1*(rs1229984) + β2*(peer_drinking) + β3*(rs1229984*peer_drinking)).
The possibility of a gene-environment correlation between ADH1B rs1229984 and peer drinking
was also assessed because genetic factors influence selection of peers who drink (Fowler et al.,
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2007) and inadequate control of this correlation could produce false interactions. Using logistic
regression, the outcome peer drinking was modeled with the variables of the ADH1B variant,
gender, and ethnicity.

Secondary Analyses
Secondary analyses were performed to test the robustness of our primary findings. First,
association of the ADH1B rs1229984 variant with the milestone of age of drinking initiation was
examined in the entire sample, which included adolescent never-drinkers (N=2,410). Second,
analyses stratified by ancestry were performed to examine the main and interaction effects within
the subpopulations of European and African Americans.
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3.4 RESULTS

Participant Characteristics
Demographic, behavioral, and genotypic characteristics of the study samples are
presented in Table 3.1. The sample of ever-drinkers before age 18 used in the primary analyses
consisted of 1,550 individuals from 1,151 nuclear families (defined by full-siblings) and 645
extended families. The mean first interview age was 17, 49% were female, and the majority
came from high-risk families (89%) and were European American (73%). Before age 18, 74%
had a first intoxication and 44% experienced a first DSM-5 symptom of alcohol use disorder.
From ages 12 to 17, 39% reported that most or all of their best friends drank alcohol. Consistent
with the expected population frequencies of the ADH1B variant, 6% carried at least one copy of
the protective A allele (8% in European Americans and 3% in African Americans).

Effect of Peer Drinking
Most/all best friends drinking compared to none/few best friends drinking between ages
12-17 was associated with a main hazardous effect in univariate and multivariate models of early
drinking behaviors (Table 3.2). In the final interaction model set with GxE product terms, selfreported peer drinking had a robust effect on first intoxication (Hazards ratio (HR)=1.81, 95% CI
1.62-2.01) and first DSM-5 symptom (HR=2.17, 95% CI 1.88-2.50). In secondary analyses
examining all four responses for best friends drinking (none, few, most, all), an increase in the
number of best friends drinking was similarly related to the first intoxication (multivariate model
set with none as the reference; few HR=1.72, 95% CI 1.44-2.05; most HR=2.65, 95% CI 2.203.18; all HR=3.69, 95% CI 2.93-4.64) and first DSM-5 symptom (multivariate model set with
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none as the reference; few HR=2.43, 95% CI 1.77-3.33; most HR=4.29, 95% CI 3.12-5.92; all
HR=5.84, 95% CI 4.16-8.21). These results indicate a “dosage effect” where the reported
proportion of best friends drinking was positively associated with higher risk for developing
adolescent drinking milestones.

Effect of ADH1B rs1229984 Variant
During adolescence, presence of the ADH1B variant (GA/AA genotypes) was associated
with a protective main effect among ever-drinkers for first intoxication and first DSM-5
symptom in univariate and multivariate models (Table 3.2). In the final interaction model set
with GxE product terms, the effect of the ADH1B variant was strong for both first intoxication
(HR=0.56, 95% CI 0.41-0.76) and first DSM-5 symptom (HR=0.45, 95% CI 0.26-0.77). In
secondary analyses of the entire sample that included never-drinkers, presence of the variant
exhibited no effect on drinking initiation (HR in univariate model=1.12, 95% CI 0.92-1.36),
consistent with the mechanism of the variant of only exhibiting an effect in response to alcohol
consumption.

Interaction between ADH1B rs1229984 and Peer Drinking
The interaction between the ADH1B variant and peer drinking was tested by adding GxE
product term to models of drinking milestones in adolescent drinkers (N=1,550), which
illustrated a significant statistical interaction for first intoxication (p=.002) and first DSM-5
symptom (p=.01) (Table 3.2). Among individuals who reported none/few best friends drinking,
the ADH1B GA/AA genotypes had a strong protective effect for first intoxication (HR=0.56,
95% CI 0.41-0.76) and first DSM-5 symptom (HR=0.45, 95% CI 0.26-0.77). In individuals who
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reported most/all best friends drinking, however, this protective effect was not observed for
either first intoxication (HR=1.16, 95% CI 0.82-1.65) or first DSM-5 symptom (HR=1.03, 95%
CI 0.73-1.45), as illustrated by the point estimates close to 1. Figure 3.2 more clearly illustrates
this GxE interaction by presenting the survival estimates.

Association between ADH1B Variant and Peer Drinking
No evidence of a gene-environment correlation between the ADH1B variant and peer
drinking was observed. Specifically, the independent variable of the ADH1B rs1229984 variant
was not significant in the logistic regression model of perceived peer drinking controlling for sex
and ethnicity as covariates (most/all vs none/few best friends drink, Odds Ratio=1.19, 95% CI
0.78-1.83).

Assessment of Robustness of Results
The proportional hazards assumption was satisfied in first DSM-5 symptom models.
Violations were noted in a subset of first intoxication analyses. Examination of Scholenfeld
residuals indicated that the group of 17 year olds was driving this violation, perhaps reflecting
important transitions at this age. Censoring at age 17 instead of 18 satisfied the proportional
hazards assumption without substantially altering the parameter estimates, supporting our
conclusions.
Ancestry-stratified analyses demonstrated consistent main and interaction effects in the
European American subpopulation (N=1,130). In the interaction model set for European
American individuals, peer drinking had a hazardous effect on first intoxication (HR=1.87, 95%
1.66-2.11) and first DSM-5 symptom (HR=2.23, 95% CI 1.89-2.63); rs1229984 had a protective
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effect on first intoxication (HR=0.60, 95% CI 0.44-0.82) and first DSM-5 symptom (HR=0.47,
95% CI 0.27-0.82); and interaction terms were significant (p<.02). The ADH1B GA/AA
genotypes were protective among individuals reporting none/few best friends drinking, but not
among those reporting most/all best friends drinking, corroborating our findings in the overall
sample.
Stratified analyses of African Americans (N=420) provided trending evidence of main
effects. In the interaction model set with GxE product terms, peer drinking had a hazardous
effect on first intoxication (HR=1.62, 95% 1.27-2.08) and first DSM-5 symptom (HR=1.98, 95%
CI 1.50-2.61); rs1229984 had a trending protective effect on first intoxication (HR=0.32, 95% CI
0.08-1.27) and first DSM-5 symptom (HR=0.35, 95% CI 0.05-2.28); and interaction terms were
insignificant (p>.7). The limited sample size of African Americans combined with the low
frequency of the rs1229984 minor allele limits power to detect interactions in this analysis.
Nonetheless, the robust effect of peer drinking in both ancestry groups and the well-established
role of rs1229984 across ancestry groups lends support for our conclusions drawn from the
combined sample.
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3.5 DISCUSSION

Alcohol use behaviors established during adolescence are important contributing factors
for the later progression to alcohol dependence (Grant et al., 2006; Pitkanen et al., 2005). These
data provide an example of the important interplay of genetic and environmental risks in the
development of drinking milestones during this critical period of adolescence. Using a
longitudinal sample of European and African American adolescent drinkers, we demonstrate that
the ADH1B rs1229984 minor A allele is associated with a protective effect for early drinking
behaviors, and in the environmental high-risk context of most or all best friends drinking, this
genetic protection is negated.
The observation that the ADH1B variant is associated with a decreased risk of first
intoxication and first DSM-5 symptom during adolescence (Table 3.2) extends previous findings
that this variant protects against alcohol-related health problems in adulthood ( Bierut et al.,
2012; Gelernter et al., 2014; Li et al., 2011). Despite having an early role in the trajectory of
drinking behaviors, the ADH1B variant was not associated with drinking initiation, consistent
with the hypothesized mechanism of action that requires alcohol exposure (Edenberg and
Foroud, 2013; Hurley and Edenberg, 2012). This specific example of a genetic variant that
influences early drinking milestones, but not initiation, builds on twin and adoption study
findings that genetic factors contribute to the development of adolescent alcohol-related
problems, and environmental factors more strongly drive drinking initiation (Hopfer et al., 2003;
Lynskey et al., 2010).
Beyond demonstrating an early protective role of the ADH1B GA/AA genotypes in the
development of these drinking behaviors, the results illustrate that reporting most or all best
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friends drinking was associated with attenuation of this genetic protection (Figure 3.2). The
observation that social context modifies the effect of an ADH1B variant extends previous studies
on alcohol metabolizing variants. Higuchi et al. (1994) found that the proportion of alcohol
dependent adults in Japan with one copy of a protective aldehyde dehydrogenase 2 (ALDH2)
variant increased between 1979 and 1992, following the increased cultural pressure to drink
alcohol. Similarly, Irons et al. (2007) reported that the high-risk environment of sibling substance
use was associated with a diminished effect of this ALDH2 variant in East Asian adolescent
adoptees, and more recently, this group demonstrated that high parental alcohol use and misuse
reduced the effect of the ALDH2 protective allele (Irons et al., 2012). For the ADH1B rs1229984
variant, Hasin et al. (2002) observed a weaker protective role in certain groups, which was
hypothesized to reflect differences in environmental exposure to heavy drinking. Our findings
expand on these earlier observations by demonstrating that the critical high-risk social context of
adolescent peer drinking is associated with the loss of the protective genetic effect of the ADH1B
variant in European and African Americans.
Previous studies of metabolizing variants have focused on Asian populations where the
ADH1B rs1229984 A allele is common, and only recently was this variant associated with
alcoholism at a genome-wide level in an European and African American sample (p=6.6x10-10)
(Bierut et al., 2012). A recent GWAS of alcohol dependence further supports a strong effect of
this variant in European Americans (p=1.17x10-31) (Gelernter et al., 2014). To our knowledge,
this study is the first to examine the effect of the ADH1B rs1229984 variant on adolescent
drinking behaviors and incorporate environmental moderation in European and African
Americans.
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One challenge of studying the influence of the ADH1B rs1229984 variant in populations
of European and African ancestry is the low frequency of the protective A allele. Although over
1,500 adolescent drinkers were examined in this analysis, only 98 (6%) carried an A allele (of
which 36 reported most/all best friends drinking). Nonetheless, the influence of this variant and
the GxE interaction was persistently strong in models of first intoxication and first DSM-5
symptom (Table 3.2). Secondary ancestry-stratified analyses also demonstrated consistent main
and interaction effects in the European American subpopulation (N=1,130) and provided
trending evidence of main effects in the African American subpopulation (N=420), where power
was limited. These analyses, combined with previous studies supporting the protective role of
rs1229984 across ancestry groups as well as the moderating effect of social environments,
support our conclusion that this variant is associated with a protective effect for early drinking
behaviors in European and African Americans, but this genetic protection may be eliminated by
adolescent peer drinking.
The findings reported here have several limitations. First, studying a specific genetic
variant provides limited information on the general genetic underpinnings of complex diseases
such as alcohol use disorder (Dick and Kendler, 2012). Nevertheless, examination of specific
robust variants provides important insight into underlying biological mechanisms that are not
assessed by traditional studies of latent genetic influences. Second, other genetic variants may
influence associations between ADH1B rs1229984 and drinking behaviors (Meyers et al., 2013;
Toth et al., 2011). Third, self-reported peer drinking was viewed as an environmental risk factor
in this study, but research suggests that genetic factors contribute to peer alcohol involvement
(Fowler et al., 2007). Gene-environment correlations can arise when an individual’s heritable
behavior evokes an environmental response (evocative rGE) or when an individual possesses a
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heritable propensity to select an environment (active rGE). In this study, the ADH1B rs1229984
variant was not associated with self-reported peer drinking, supporting our interpretation that
peer drinking acts as an environmental modifier, but other gene-environment correlations may
still contribute to the observed effects. Fourth, the temporal ordering of peer drinking and the
onset of drinking behaviors could not be assessed in this study (Table 3.1). It is possible that
other risk factors correlated with peer drinking, such as parental monitoring or genetic risk for
anti-social behavior, may account for the observed associations. Fifth, peer drinking was
assessed by respondent report and may not reflect the actual proportion of best friends drinking.
Finally, the majority of participants were from high-risk families, which may limit the
generalizability of the findings. It is possible that only individuals at high-risk for alcohol use
disorders lose the protective effect of the ADH1B rs1229984 variant under environments that
encourage drinking. Replication of these findings in independent samples is a critical next step.
Despite these limitations, this study has several strengths. First, the analysis focused on a
genetic variant with strong statistical and biological evidence for alcohol-related measures,
which addresses common criticisms of GxE studies (Duncan and Keller, 2011; Joober et al.,
2007; Risch et al., 2009). Second, focusing on a youth population and employing a longitudinal
study design reduced recall bias, enabling more accurate assessment of drinking behaviors
during the critical period of adolescence. Third, the robust environment of respondent report of
best friends drinking from ages 12-17 coincided with the timing of the primary outcomes under
study. This analysis focused on drinking behaviors that are common in adolescence and therefore
are more likely to be directly influenced by peer drinking during this period. Finally, studying
adolescent drinking milestones facilitated the characterization of the unfolding of genetic and
environmental risks across development. Recent studies further support the discovery potential
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of examining genetic variants during important behavioral transitions in at-risk youth (Belsky et
al., 2013; Dick et al., 2013). Future research on alcohol use disorders may benefit from similar
hypothesis-driven study designs that examine well-established genes and environments during
critical developmental periods.
From a public health perspective, this study provides a genetic argument in support of
early social interventions to decrease affiliation with peer drinkers. Specifically, these findings
support the use of a screening tool for practitioners to identify at-risk youth, developed by the
National Institute on Alcohol Abuse and Alcoholism and the American Academy of Pediatrics,
in which the first question addresses friends’ drinking (NIAAA, 2011). Under the high-risk
environment of best friends drinking, all adolescents were at increased risk for early drinking
problems, and particularly, those at lower genetic risk experienced the greatest added risk. This
study serves as a model of how understanding the interplay between genes and environments
may increase etiological knowledge of alcohol use disorders and potentially inform interventions
that aim to disrupt progression to alcoholism.
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3.8 TABLES
Table 3.1. Characteristics of samples used in analyses
Characteristic

Entire sample (N=2,410)

Ever-drinkers before age 18
(N=1,550)

1,648 (68.4)
762 (31.6)

1,130 (72.9)
420 (27.1)

1,182 (49.1)
1,228 (51.0)

784 (50.6)
766 (49.4)

16.3 ± 3.2
12-22

16.7 ± 3.0
12-22

3.2 ± 1.1
(1-5)

3.2 ± 1.1
(1-5)

2,096 (87.0)
314 (13.0)
781

1,384 (89.3)
166 (10.7)
645

1,629
1,438

1,151
1,044

2 (1-24)

2 (1-17)

1,573 (65.3)
1,170 (48.6)
702 (29.1)

1,550 (100.0)
1,147 (74.0)
683 (44.1)

15.3 (1.5)
8-17

15.4 (1.4)
12-17

15.6 (1.3)
10-17

15.6 (1.2)
12-17

2,270 (94.2)
137 (5.7)
3 (0.1)

1,452 (93.7)
96 (6.2)
2 (0.1)

746 (31.0)
981 (40.7)
513 (21.3)
170 (7.1)

239 (15.4)
708 (45.7)
453 (29.2)
150 (9.7)

Ancestry, N (%)
European
African
Sex, N (%)
Males
Females
Age at first interview, years
Mean ± sd
Range
No. of interviews
Mean ± sd
Range
Family status, N (%)
From high-risk families
From comparison families
No. of extended families
No. of nuclear families
Only full-siblings
Including half-siblings
No. of individuals per extended family,
median (range)
Drinking milestones reached before age 18,
N (%)
First drink
First intoxication
First DSM-5 symptom
Among those who exhibit a first intoxication
before age 18
Mean age ± sd
Age range
Among those who exhibit a first DSM-5
symptom before age 18
Mean age ± sd
Age range
rs1229984, N (%)
GG
GA
AA
Reported proportion of best friends who use
alcohol between ages 12-17, N (%)
None
Few
Most
All
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Table 3.2. Cox proportional hazards regression models of adolescent drinking milestones
Drinking milestones in ever-drinkers before age 18 (N=1,550)
Models of first intoxication

Models of first DSM-5 symptom

Hazard ratio
(95% CI)

χ p
value

2

Hazard ratio
(95% CI)

χ p
value

2

0.72 (0.56-0.91)

.006

0.69 (0.50-0.94)

.02

1.89 (1.70-2.10)

<.0001

2.27 (1.98-2.60)

<.0001

rs1229984

0.76 (0.61-0.96)

.02

0.73 (0.54-0.97)

.03

peer drinking

1.88 (1.69-2.09)

<.0001

2.26 (1.97-2.60)

<.0001

Univariate model set
rs1229984

a

peer drinking

b

Multivariate model set

Interaction model set

a

rs1229984

0.56 (0.41-0.76)

.0002

0.45 (0.26-0.77)

.004

peer drinking

1.81 (1.62-2.01)

<.0001

2.17 (1.88-2.50)

<.0001

rs1229984*peer drinking

2.10 (1.32-3.32)

.002

2.29 (1.21-4.30)

.01

Examination of GxE term in interaction model
set
None/few best friends drink (GA/AA vs GG)

0.56 (0.41-0.76)

.0002

0.45 (0.26-0.77)

.004

Most/all best friends drink (GA/AA vs GG)

1.16 (0.82-1.65)

.39

1.03 (0.73-1.45)

.87

Reference ADH1B rs1229984 genotype GG was compared to GA/AA; b Reference peer

drinking status none/few best friends drink was compared to most/all best friends drink; All
models adjusted for gender and ethnicity.
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3.9 FIGURES

Figure 3.1. Sample selection for study analyses. European and African American adolescent
ever-drinkers with ADH1B rs1229984 genotyping were drawn from the Collaborative Study on
the Genetics of Alcoholism (COGA) for the primary analyses of two early drinking milestones.
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Figure 3.2. Survival estimates of drinking milestones stratified by ADH1B rs1229984 genotype
and perceived best friends drinking. Cox proportional hazards regression survival estimates of (A) first
intoxication and (B) first DSM-5 alcohol use disorder symptom in adolescent ever-drinkers (N=1,550)
with the variables of ADH1B genotype, best friends drinking, and GXE interaction term.
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CHAPTER FOUR:
CYP2A6 metabolism in the development of nicotine dependence in young adults
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4.1 ABSTRACT

The gene CYP2A6 encodes the enzyme responsible for the majority of nicotine metabolism.
Previous studies support that slow metabolizers smoke fewer cigarettes once nicotine dependent,
but provide conflicting results on the role of CYP2A6 in the development of dependence. By
focusing on the critical developmental period of young adulthood, this study examines the role of
variation in CYP2A6 on different smoking milestones. A total of 1,102 European Americans with
a last interview age from 19-30 years enrolled in the Collaborative Study on the Genetics of
Alcoholism were genotyped for CYP2A6 variants to calculate a previously well-validated
nicotine metabolism metric. This metric was not associated with smoking initiation or the
development of daily smoking (p>0.5), but among daily smokers (n=468), decreased metabolism
was associated with increased risk of nicotine dependence (defined as Fagerstrom Test for
Nicotine Dependence score ≥4) after controlling for sex, study site, age of last interview, and
familial relatedness (p=0.03). This finding was replicated in 335 daily smokers ages 25-30 years
enrolled in the Collaborative Study of Nicotine Dependence (p=0.02). Meta-analysis indicated
that slow metabolizers (defined by a metric≤0.85) had a 1.64 increased odds (95% CI 1.17-2.28,
p=0.004) of developing nicotine dependence as compared to normal metabolizers (metric>0.85).
Overall, these findings add important knowledge about the complex role of CYP2A6 variation
across different developmental stages of smoking behaviors. Although slow metabolism may be
protective for cigarette consumption among nicotine dependent adults, we show that slow
metabolism is associated with an increased risk of developing nicotine dependence in young
adult daily smokers.
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4.2 INTRODUCTION

The development of nicotine dependence requires smoking initiation, conversion from
experimental to daily use, and finally the development of advanced smoking behaviors (Belsky
et al., 2013; Bierut, 2011). Although the majority of adult smokers initiate smoking during
adolescence, rates of daily smoking substantially increase during young adulthood among eversmokers (22% at ages 12-17, 52% at ages 18-34, 62% at ages 35 or more) (NSDUH, 2012).
Furthermore, among those who report smoking within the past 30 days, the proportion of
individuals that smoke more than approximately a pack a day also dramatically increases with
age (6% at ages 12-17, 23% at ages 18-34, and 44% at ages 35 or more) (NSDUH, 2012).
Increasing our knowledge of what factors drive some young adults and not others to transition
from initiation to daily smoking and then later smoking behaviors is important for effectively
preventing the progression of nicotine dependence.
One genetic factor that may play an important role in the development of smoking
behaviors is variation in the gene CYP2A6, which encodes a cytochrome P450 enzyme. This
enzyme is responsible for the majority of oxidation of nicotine to cotinine, which is the primary
pathway of nicotine metabolism in humans (Hukkanen et al., 2005). The CYP2A6 locus is highly
polymorphic, and alleles with reduced function have been associated with slower rates of
nicotine metabolism. Common variants define multiple CYP2A6 haplotypes in European
ancestry individuals (Haberl et al., 2005), and the majority of inter-individual variation in the
metabolism of nicotine to cotinine is explained by targeted polymorphisms in European
Americans (Bloom et al., 2011).
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In adults, the region on chromosome 19 encompassing CYP2A6 is genome-wide
significant in large meta-analyses focused on cigarettes per day in European ancestry populations
(TAG, 2010; Thorgeirsson et al., 2010). Among nicotine dependent adults, the majority of
studies demonstrate that genetically slower metabolizers smoke fewer cigarettes per day. This
observation is thought to reflect the fact that smokers naturally titrate their cigarette consumption
to maintain steady nicotine levels.
Studies in youth present conflicting results on the effect of nicotine metabolism on the
development of nicotine dependence and other smoking behaviors (Audrain-McGovern et al.,
2007; Huang et al., 2005; Moolchan et al., 2009; O'Loughlin et al., 2004; Rubinstein et al., 2008;
Rubinstein et al., 2013). Some studies suggest that slow nicotine metabolism is associated with
an increased risk for acquisition of nicotine dependence (O'Loughlin et al., 2004; Rubinstein et
al., 2013), possibly reflecting an increased sensitivity to initial nicotine exposure among youth
that metabolize nicotine more slowly. In contrast, other studies suggest that slower metabolizers
have a decreased risk for dependence and related symptoms (Audrain-McGovern et al., 2007;
Rubinstein et al., 2008), paralleling findings in adults regarding heaviness of smoking.
Our goal was to investigate how variation in CYP2A6 influences the development of
nicotine dependence and other smoking behaviors during the critical period of young adulthood
in European Americans. A better understanding of how variation in nicotine metabolism
contributes to the acquisition of smoking milestones will add to our fundamental knowledge of
the developmental processes that lead to nicotine dependence and has the potential to identify
individuals at increased susceptibility during this critical period.
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4.3 MATERIALS AND METHODS

Primary Sample Description
The Collaborative Study on the Genetics of Alcoholism (COGA) is a United States multicenter, family study that aims to identify genes that contribute to alcohol use disorders and
related phenotypes (Begleiter et al., 1995). Since 2005, the adolescent and young adult study in
COGA has used a longitudinal design to examine the development of substance use disorders in
youth from high-risk (defined as recruited through alcohol dependent probands with two or more
dependent first degree relatives) and community comparison families. Members aged 12 to 22
were recruited from six sites across the US and interviewed every two years.

Smoking Behaviors in COGA
Interview assessments were performed using the Semi-Structured Assessment for the
Genetics of Alcoholism (SSAGA), which comprehensively gathers detailed information on
substance use with high reliability and validity (Bucholz et al., 1994; Bucholz et al., 1995;
Hesselbrock et al., 1999). Smoking initiation was evaluated with the question “Have you ever
smoked a full cigarette?” Daily smoking, defined as smoking at least 4 days per week for at least
a month, was assessed among individuals who had initiated smoking using the questions “How
many cigarettes did you usually smoke a day” and “For how long, did you smoke this many
cigarettes at that rate?”
Among individuals who reported daily smoking, several measures of late smoking
behaviors were assessed that focused on the period of heaviest smoking. Time to first cigarette
after waking was derived from the question “During this period when you were smoking the
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most, about how many minutes after you woke up did you smoke your first cigarette?” and the 4
answers: more than one hour, 31-60 minutes, 6-30 minutes, and within 5 minutes. For the
primary analyses, time to first cigarette was dichotomized into >5 minutes and ≤5 minutes after
waking. Cigarettes per day was evaluated with the question “During the period of time when you
were smoking the most, about how many cigarettes did you usually have per day?” and the 4
answers: 10 or fewer, 11-20, 21-30, and 31 or more cigarettes. Cigarettes per day was
dichotomized into ≤20 and >20 cigarettes in the primary analyses as done in previous studies
(Belsky et al., 2013). A total Fagerstrom Test for Nicotine Dependence (FTND) score during the
heaviest period of smoking was calculated at each interview using responses to these 2 questions
as well as responses to questions assessing the four remaining criteria (details in Heatherton et
al., 1991). For the primary analyses, nicotine dependence was defined as a FTND score of 4 or
more.
Given the longitudinal design of this study, an endorsement of smoking initiation or daily
smoking at any interview was used to capture these behaviors. The highest FTND score across
available interviews was chosen to capture the lifetime maximum, and the variables time to first
cigarette as well as cigarettes per day were set at these same interviews.

Genotyping
Recently, Bloom et al. (2011) developed a metric based on several genetic variants in
CYP2A6 to estimate nicotine metabolism. Cross-validation estimates that this metric predicts
approximately 70% of the variance in metabolism of orally administered nicotine to cotinine in
European Americans. Our goal was to use this CYP2A6 metabolism metric to test whether
CYP2A6 variation predicts cigarette smoking behaviors.
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Blood samples from COGA were obtained for genetic analysis. Five CYP2A6 single
nucleotide polymorphisms (SNPs) (rs1801272, rs28399442, rs28399433, rs1137115,
rs28399435) were genotyped using the LGC Genomics Competitive Allele-Specific PCR
(KASP), a FRET-based endpoint genotyping assay (http://www.lgcgenomics.com). PCR
reactions were run on an ABI GeneAmp PCR System 9700, and fluorescence measurements
taken on an ABI 7900HT Fast Real-Time PCR System (http://www.lifetechnologies.com). The
CYP2A6 copy number variant (CNV) was genotyped with TaqMan 5’ Nuclease Assays
(Hs00010002_cn and Hs07545275_cn, Life Technologies) using a standard qPCR protocol on
the ABI 7900HT System. The CNV assay was run in duplicate, and genotype calls were made
using CopyCaller software. The program PEDCHECK (O'Connell and Weeks, 1998) was used
to examine Mendelian inheritance, and only individuals with no Mendelian inconsistencies were
included in the genotyped sample. The metabolism metric was calculated based on the genotypes
of the five CYP2A6 SNPs and the CNV using an algorithm described in Supplemental Table 4.1
(adapted from Bloom et al., 2012).
A set of 64 ancestry informative markers was genotyped as part of a 96 SNP
Biorepository Panel by the Rutgers University Cell and DNA Repository. These markers were
used in SNPrelate, a function in R, to assign ancestry groups. HapMap populations were
included as reference groups. There was high concordance (98%) between self-reported and
genetically determined ethnicity among European Americans. Only genetically determined
European Americans were included in the analysis because the metric was optimized for this
population (Bloom et al., 2011).
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Primary Sample Selection
In the COGA adolescent and young adult study, 1,102 European ancestry individuals
with age of last interview between 19 and 30 were genotyped for the CYP2A6 variants, and
participants for the analyses were drawn from this group (Figure 1). The analysis was restricted
to individuals who had reached young adulthood because we were interested in transitions to
daily smoking and late smoking behaviors, outcomes that often occur during this time. The
sample used to analyze daily versus non-daily smokers consisted of 706 (64%) individuals who
had initiated smoking. For transitions to late smoking behaviors, we focused on the sample of
468 (66%) daily smokers (described in Table 4.1).

Replication COGEND sample
The Collaborative Study of Nicotine Dependence (COGEND) is a multi-center casecontrol study designed to identify genes that contribute to nicotine dependence (Saccone et al.,
2007). Community based recruitment enrolled participants ages 25-45 years old. Cases were
required to be current smokers and have an FTND score of 4 or more. Controls were required to
have smoked at least 100 cigarettes and have a lifetime maximum FTND score of 1. For this
analysis, only subjects who self-identified as being of European ancestry were examined, and
previous analyses using EIGENSTRAT have shown a high correspondence with genetically
determined ancestry groups (Saccone et al., 2009). Genotyping of variants to calculate the
metabolism metric in COGEND has been previously described (Bloom et al., 2012). We focused
on the subsample of 377 COGEND young adults ages 25-30, which overlapped with the age
range of the COGA young adult sample. From this group, 335 (89%) reported smoking every
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day or nearly every day for at least 2 months and were considered daily smokers. Replication
sample characteristics of these daily smokers are described in Table 4.1.

Primary Data Analysis
Data were analyzed using the Statistical Analysis System. Logistic regression was used to
model dichotomous outcomes of daily smoking, nicotine dependence, time to first cigarette, and
cigarettes per day. In the primary analyses in COGA and COGEND, the continuous metabolism
metric, sex, study site, and last interview age were included as variables. In COGA, family
structure was accounted for using generalized estimating equations via PROC GENMOD.
Results from the COGEND replication sample were meta-analyzed with the primary COGA
results (Table 4.2) using a publically available SAS macro
(http://www.hsph.harvard.edu/spiegelman/metaanal.html). Meta-analyses results were based on
fixed effect models to determine the evidence for association within the collected samples. In
these analyses, we did not observe heterogeneity between the two studies based on the Q statistic
(p>0.1).

Secondary Data Analyses
Several secondary analyses were performed to test the robustness of our primary
findings. First, individuals were divided into slow and normal metabolizers using a cut-off of
≤0.85 on the metabolism metric as done in previous studies (Chen et al., 2014). This cut-off
represents approximately the lowest quartile of metabolizers and this dichotomous variable was
examined in logistic regression models of smoking behaviors. Second, the 4 level variable of
time to first cigarette after waking (>60, 31-60, 6-30, ≤5 minutes) was also investigated in
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cumulative logistic regression models to assess whether the metabolism metric predicted
response across these four ordinal categories. Third, because FTND contains information about
time to first cigarette, we also examined the equation predicting dichotomous nicotine
dependence with this added variable of time to first cigarette. Finally, we calculated FTND
scores without the question regarding time to first cigarette after waking and explored the
association between the metabolism metric and this new alternative nicotine dependence
measure. Without the important question of time to first cigarette after waking, this alternative
score was ≥4 for only 25% (115/461) of young adult daily smokers in COGA and 26% (87/335)
in COGEND.
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4.4 RESULTS

Participant Characteristics
Demographic, behavioral, and metabolism metric characteristics of the COGA and
COGEND samples are presented in Table 4.1. The primary COGA sample of young adult daily
smokers consisted of 468 European American individuals from 401 nuclear families and 293
extended families. The mean age at last interview was 24: 44% were female, and the majority
came from families at high-risk for alcoholism (92%). Among these daily smokers, 59% were
nicotine dependent, 32% smoked within 5 minutes after waking, and 26% smoked greater than
20 cigarettes per day (Figure 4.1 and Table 4.2). Twenty-six percent of the young adults were
slow metabolizers, and the distribution of the metabolism metric (Supplemental Figure 4.1) was
similar to that seen in other samples (Bloom et al., 2012; Chen et al., 2014).
The COGEND replication sample of young adult daily smokers consisted of 335
European Americans with an average age at interview of 28, and the majority were female
(61%). Among COGEND young adult daily smokers, 50% were nicotine dependent, 24%
smoked within 5 minutes after waking, 25% smoked greater than 20 cigarettes per day, and 30%
were slow metabolizers (distribution in Supplemental Figure 4.1) .

CYP2A6 Metabolism Metric and Early Smoking Behaviors
The CYP2A6 metabolism metric was not associated with smoking initiation (p=0.51) and
the development of daily smoking (p=0.57) in the COGA young adults (Table 4.2). Therefore,
subsequent analyses of late smoking milestones focused on the 468 daily smokers. Of the 238
young adults who initiated smoking but did not transition to daily smoking, essentially all of
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them (99.6%) failed to develop any of the late smoking behaviors. This supports the notion that
daily smoking is a prerequisite for the development of late smoking behaviors.

CYP2A6 Metabolism Metric and Late Smoking Behaviors in Daily Smokers
CYP2A6 haplotypes predictive of slower metabolism were associated with an increased
risk of nicotine dependence in both the primary COGA and replication COGEND samples of
young adult daily smokers (Table 4.2, Figure 4.2). In multivariate models adjusting for age, sex,
and study site, the continuous CYP2A6 metabolism metric had a significant effect in COGA (p
=0.03) and COGEND (p=0.02), where a slow predicted metabolism was associated with an
increased risk of nicotine dependence defined by an FTND score ≥4 (Table 4.2). Secondary
analyses showed that slow metabolizers (defined by a metric of ≤0.85) had a 1.64 increased odds
(95% CI 1.17-2.28, p=0.004) of developing nicotine dependence as compared to normal
metabolizers (metric>0.85) in meta-analyses of COGA and COGEND studies (Supplemental
Table 4.2). Figure 4.2 illustrates this association by showing that a larger proportion of slow
metabolizers in both COGA and COGEND developed nicotine dependence as compared to
normal metabolizers.
Consistent with the nicotine dependence results, a lower metabolism metric was
associated with an increased risk of smoking within 5 minutes after waking (Table 4.2, Figure
4.2). The continuous CYP2A6 metabolism metric had a trending effect in COGA (p=0.07) and a
significant effect in COGEND (p=0.01). In meta-analysis, slow metabolizers had a 1.61
increased odds (95% CI 1.15-2.26, p=0.006) of smoking within 5 minutes after waking
compared to normal metabolizers (Supplemental Table 4.2, Figure 4.2). The CYP2A6
metabolism metric was not associated with smoking more than 20 cigarettes per day in both
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samples (Table 4.2), and Figure 4.2 illustrates that a similar proportion of slow and fast
metabolizers reported smoking more than 20 cigarettes per day.

Robustness of effect of CYP2A6 Metabolism Metric on Time to First Cigarette after
Waking
Examination of all 4 responses of time to first cigarette after waking (≥60, 31-60, 6-30,
≤5 minutes) in secondary analyses demonstrated a slightly more robust effect of the metabolism
metric in both COGA (p=0.06) and COGEND (p=0.004) as compared to the dichotomous
variable of time to first cigarette (>5 and ≤5 minutes) (Supplemental Table 4.3 and Table 4.2,
respectively). Supplemental Figure 4.2 illustrates that across the 4 categories, there was an
increased proportion of slow metabolizers at shorter times to first cigarette after waking among
COGA daily smokers. In COGEND daily smokers, we observed a similar trend, except in the
category of 31-60 minutes that only had 19 individuals (6% of sample, Table 4.1). Taken
together these results support a possible “dosage effect” where predicted slower metabolism was
correlated with smoking sooner after waking.
Since time to first cigarette after waking contributes to the calculation of FTND score,
we also examined the effect of the metabolism metric on nicotine dependence after controlling
for time to first cigarette after waking as a variable. In COGEND, the metabolism metric was no
longer a significant predictor of nicotine dependence (p=0.23) and in COGA the significance was
diminished (p=0.04) (Supplemental Table 4.4). Furthermore, when FTND scores were
calculated excluding the time to first cigarette after waking question, there was essentially no
association between the metabolism metric and this adjusted measure of nicotine dependence
(COGA p=0.51 and COGEND p=0.69, Supplemental Table 4.4). These results suggest that our
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primary association between the CYP2A6 metabolism metric and nicotine dependence is driven
by time to first cigarette after waking.
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4.5 DISCUSSION

Young adulthood is a critical developmental period for the progression from initiation to
late smoking milestones (NSDUH, 2012). This study links variation in a genome-wide
significant gene, CYP2A6, with the development of smoking behaviors in two independent
samples of European American young adults. Using specific CYP2A6 polymorphisms, we
calculated a nicotine metabolism metric, which has been previously shown to account for
approximately 70% of the variance in metabolism of orally administered nicotine to cotinine in
European Americans (Bloom et al., 2012; Bloom et al., 2011). Our primary finding is that
decreased predicted nicotine metabolism is associated with an elevated risk of developing
nicotine dependence among young adult daily smokers, adding important insight into the role of
variation in CYP2A6 across stages of smoking development, as illustrated in Figure 4.3.
Despite having an important role in the development of nicotine dependence, variation in
CYP2A6 was not associated with smoking initiation or the progression to daily smoking (step 1
in Figure 4.3). Previous twin studies support that environmental influences primarily drive early
adolescent nicotine use, and that the role of heritable factors on smoking behaviors increases
throughout young adulthood (Kendler et al., 2008; Koopmans et al., 1999). Our results are
consistent with this model by providing evidence of a gene that impacts the transition from daily
smoking to nicotine dependence, without influencing initiation and daily smoking.
The observation that decreased predicted nicotine metabolism is associated with
increased risk of nicotine dependence in young adults also builds on previous studies conducted
in adolescents (step 2 in Figure 4.3). O’Loughlin et al. (2004) followed 228 non-dependent
smokers in grade 7 over approximately 30 months and found that those with inactive genetic
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variants in CYP2A6 were more likely to develop nicotine dependence by the international
classification of diseases (ICD-10) criteria, but smoked fewer cigarettes per day once dependent.
Huang et al. (2005) examined variation in CYP2A6 in 1,518 adolescents enrolled in a
longitudinal study in the United Kingdom and similarly found that individuals with inactive
variants associated with slower metabolism were more likely to be current versus former
smokers at age 18 compared to normal metabolizers. More recently, Rubinstein et al. (2013)
assessed a biomarker of the rate of nicotine metabolism (the nicotine metabolite ratio) in 164
adolescent smokers and found that slower metabolizers showed greater symptoms of dependence
on the modified Fagerstrom Tolerance Questionnaire. Our findings expand on these earlier
results by demonstrating that during young adulthood, when many late smoking behaviors
develop, slow metabolizers continue to have a greater risk of dependence.
The increased susceptibility to developing nicotine dependence encountered by youth
slow metabolizers has been hypothesized to reflect prolonged exposure to nicotine during initial
smoking experiences (Chenoweth et al., 2013; Malaiyandi et al., 2005; Rubinstein et al., 2013).
Although accumulating evidence support this role, it is important to note that a few studies show
the opposite effect where slow metabolism is associated with decreased risk of smoking
behaviors in youth (Audrain-McGovern et al., 2007; Moolchan et al., 2009; Rubinstein et al.,
2008). For example, Audrain-McGovern (2007) examined 222 European ancestry adolescent
ever-smokers and found that normal CYP2A6 metabolizers developed symptoms of dependence
on the modified Fagerstrom Tolerance Questionnaire at a faster rate than slower CYP2A6
metabolizers. Many possible explanations exist for these discrepant results, including differences
in measures of nicotine metabolism and dependence.
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Our results suggest that time to first cigarette after waking is a critical contributor to the
association between the CYP2A6 metabolism metric and nicotine dependence assessed by the
FTND criteria. Little consensus exists on the best measure of nicotine dependence, but research
supports that two items from the FTND score, time to first cigarette after waking and cigarettes
per day, are strong, valid, reliable predictors of quitting behaviors, which are key indicators of
dependence (Baker et al., 2007; Borland et al., 2010; Hyland et al., 2006). Studies also suggest
that these two measures are distinct predictors of addiction (Borland et al., 2010; Lessov et al.,
2004), suggesting the possibility that different genetic factors may contribute to urgency to
smoke and levels of cigarette consumption. In a sample of over 1000 young adults, Haberstick et
al. (2007) found that time to first cigarette was the most informative measure of heritable factors
from the FTND score. Our results complement these findings by illustrating that necessity to
smoke measured by time to first cigarette after waking drives the association of the CYP2A6
metabolism metric and nicotine dependence in young adults.
These findings in young adults should be considered in the context of the adult literature.
Previous studies of adults demonstrate that once dependent, genetically slower metabolizers
smoke fewer cigarettes to reach target blood nicotine levels (Benowitz, 2008) (step 3 in Figure
4.3). Although we did not observe an effect of slow metabolism on risk of smoking more than 20
cigarettes per day among daily smokers (Table 4.2, Figure 4.2), only 26% of these young adults
were heavy smokers, and heaviness of smoking continues to increase throughout adulthood
(NSDUH). In the entire COGEND sample ages 25-45, previous work suggests that once
dependent, slower metabolism is associated with decreased cigarette consumption (Bloom et al.,
2012). These findings underscore that variation in CYP2A6 has a variety of effects on smoking
behaviors across stages of development in the COGEND sample: slow metabolism leads to
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increased risk for developing nicotine dependence in young adult daily smokers, but once
dependent, slow metabolism is protective for heaviness of smoking.
Another important consideration is that the fraction of slow metabolizers in the
population of smokers has been observed to decrease with age, suggesting that slow metabolizers
are more likely to quit smoking (Benowitz, 2008) (step 4 in Figure 4.3). Among COGEND
dependent current smokers ages 25-30 years, we found that 36% (60/166) were slow
metabolizers. However, among COGEND current dependent smokers over 30 years old, only
28% (250/883) were slow metabolizers, supporting that proportionally more slow metabolizers
have quit by this time. Furthermore, other studies directly support that slow nicotine
metabolism, measured by CYP2A6 genotypes or the nicotine metabolite ratio, is associated with
increased cessation rates in both youth (Chenoweth et al., 2013) and adults enrolled in clinical
trials (Ray 2009; Chen 2014). Taken together, these findings suggest that across development,
slow metabolizers may quit smoking more easily. Therefore, the observation that slow
metabolism is associated with increased risk of nicotine dependence may be most pronounced in
samples of youth when symptoms of dependence are first developing and before cessation
attempts occur.
The findings reported here have limitations. First, this study focused on European
Ancestry individuals because the metabolism metric was optimized for this population (Bloom et
al., 2011). Second, the temporal ordering of smoking behaviors could not be examined in this
analysis because the smoking questions did not assess age of onset in COGA, and COGEND is a
cross-sectional study. Third, the majority of the COGA participants were from families at high
risk for alcoholism, which may limit the generalizability of the findings. Replication of the
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primary findings in a community based recruitment sample (COGEND), however, supports that
the findings are not specific to a high-risk population.
In summary, using a validated CYP2A6 metabolism metric, this study demonstrates that
slower nicotine metabolism is associated with an increased risk of nicotine dependence in two
independent samples of young adult daily smokers. These findings add important knowledge
about the complex role of CYP2A6 variation across different developmental stages of smoking
stages. From a public health perspective, these findings and others (Belsky et al., 2013) provide a
genetic argument in support of early interventions before the development of nicotine
dependence.
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4.8 TABLES
Table 4.1. Characteristics of primary and replication samples of European American young
adults
Characteristic

Sex, N (%)
Males
Females
Age at last interview, years
Mean ± sd
Range
No. of interviews
Mean ± sd
Range
Family status, N (%)
From high-risk families
From comparison families
No. of extended families
No. of nuclear families (full siblings)
FTND score
Mean ± sd
Range
Nicotine dependence (FTND≥4), N (%)
Time to first cigarette after waking
More than 1 hour
31-60 minutes
6-30 minutes
Within 5 minutes
Cigarettes per day
10 or fewer
11-20
21-30
31 or more
Metabolism metric*
Mean ± sd
Range
Metabolism status
Low (Metric ≤ .85)
Normal (Metric > .85)

COGA Young Adult
European American
Daily Smokers (N=468)

COGEND Young Adult
European American
Daily Smokers (N=335)

264 (56%)
204 (44%)

129 (39%)
206 (61%)

23.6 ± 3.0
19-30

27.8 ± 1.7
25-30

3.6 ± 1.2
1-5

1

431 (92%)
37 (8%)
293
401

-

4.1 ± 2.6
0-10
276 (59%)

3.0 ± 3.3
0-10
166 (50%)

86 (18%)

168 (50%)

67 (15%)
167 (36%)
148 (32%)

19 (6%)
67 (20%)
81 (24%)

171 (37%)
169 (37%)
72 (16%)
48 (10%)

171 (51%)
78 (23%)
45 (13%)
41 (12%)

0.86 ± 0.07
0.44-0.90

0.86 ± 0.07
0.44-0.90

123 (26%)
345 (74%)

103 (31%)
232 (69%)

*Distribution of metabolism metric in COGA and COGEND young adult daily smokers provided
in Supplemental Figure 4.1.
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Table 4.2. Logistic regression models of smoking milestones in young adults
Metabolism Metric in
COGA Young Adults

Metabolism Metric in
COGEND Yong Adults

p-value Estimate

SE

Meta-analysis of results

Estimate

SE

p-value Estimate

SE p-value

0.67

1.03

0.51

-

-

-

-

-

-

-0.68

1.22

0.57

-

-

-

-

-

-

3.94
2.44
-0.58

1.76
1.35
1.49

0.03
0.07
0.70

4.36
4.63
1.53

1.86
1.82
1.85

0.02
0.01
0.41

4.14
3.22
0.25

Among all young adults (COGA n=1,102)
Smoking initiation
Among young adult ever-smokers (COGA
n=706)
Daily smoking
Among young adult daily smokers
(COGA n=468; COGEND n=335)
Nicotine dependence
Smoked within 5 minutes after waking
Smoked 20 cigarettes per day

1.28 0.001
1.09 0.003
1.16 0.83

All models include sex, study site, and age of last interview as covariates; Analyses with COGA
were also adjusted for familial clustering;
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4.9 FIGURES
1,102 European Ancestry Individuals in
COGA with an age of last interview of 19-30
years and CYP2A6 genotyping

706 Smoked a full cigarette (64%)

468 Smoked Daily (66%)

276 Nicotine
dependence defined as
FTND ≥4 (59%)

148 Smoked within 5
minutes after waking
(32%)

Figure 4.1. Primary COGA sample selection
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120 Smoked >20
cigarettes per day
(26%)

Normal Metabolizer

0.8

0.7

Slow Metabolizer

0.7
Proportion of Sample

Proportion of Sample

0.8

0.6
0.5

0.6
0.5

0.4

0.4
0.3
0.2

0.3
0.2
0.1

0.1

0

0
Nicotine
dependent

Smoked 5 or fewer Smoked more
minutes after than 20 cigarettes
waking
per day

Young Adult Daily Smokers in COGA
(n=468)

Nicotine
dependent

Smoked 5 or fewer Smoked more
minutes after than 20 cigarettes
waking
per day

Young Adult Daily Smokers in COGEND
(n=335)

Figure 4.2. Association between predicted metabolism and smoking behaviors in two studies of
European American young adult daily smokers. Error bars reflect standard errors.
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Early smoking behaviors

Late smoking behaviors

First Smoke
1. Early behaviors:
No effect of CYP2A6

4. Cessation:
Slow metabolizers
have increased rate

Daily Smoking

2. Transition from daily
smoking to dependence:
Slow metabolizers
have increased risk

Nicotine
Dependence

3. Heavy smoking
once dependent:
Slow metabolizers
have decreased risk
Adolescence

Young Adulthood

Heavy Smoking

Late Adulthood

Figure 4.3. A theoretical framework of the development of smoking behaviors in relation to
CYP2A6 variation
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4.10 SUPPLEMENTAL TABLES
Supplemental Table 4.1. Predicted metabolism metric and CYP2A6 diplotypes based on copy
number and 5 SNPs
CYP2A6
Copy
number

rs1801272+
rs28399442

rs28399433

rs1137115

rs8399435

0
≥1
≥1
1

0

0

0
≥1

≥1
0

2
≥1
1

0

≥1

1

0
1
0

Adapted from Bloom et al. 2012;
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0.44

*2/*12
*9
*1A
other
other

0.44
0.64
0.68
0.76
0.76

*2/*12

*2/*12

0.44

*9

0.64

*1A

0.68

≥1

*2/*12

other

0.76

*2/*12

other

0.76

*9

*9

0.76

0

*9

*1A

0.79

1

*9

other

0.85

*9

other

0.85

*1A

*1A

0.82

1

*1A

other

0.87

2

other

other

0.90

0

*1A

other

0.87

1

other

other

0.90

other

other

0.90

0
2

*4

*4
*4
*4
*4
*4

*2/*12

0
0

*4

*2/*12

0

≥2

Predicted
Metabolism
metric

0

2
1

Haplotype 2

Haplotype 1

Supplemental Table 4.2. Examination of dichotomous metabolism status as a predictor of
smoking milestones in logistic regression models in young adults
Metabolizer status in
COGA Young Adults

Metabolizer status in
COGEND Young
Adults
Odds ratio
p
(95% CI)
value

Odds Ratio
(95% CI)

p value

0.97
(0.72-1.30)

0.82

-

0.78
(0.54-1.04)

0.18

Nicotine dependence

1.51
(0.96-2.38)

Smoke within 5 minutes
Smoke greater than 20

Among all young adults (COGA
n=1,102)
Smoking initiation

Meta-analysis of
results
Odds ratio
(95% CI)

p value

-

-

-

-

-

-

-

0.08

1.79
(1.10-2.91)

0.02

1.64
(1.17-2.28)

0.004

1.44
(0.93-2.23)

0.10

1.89
(1.11-3.22)

0.01

1.61
(1.15-2.26)

0.006

0.98
(0.62-1.56)

0.94

1.13
(0.76-2.29)

0.67

1.04
(0.73-1.48)

0.82

Among young adults ever-smokers
(COGA n=706)
Daily smoking
Among young adults who smoked daily
(COGA n=468; COGEND n=335)

All models include sex, study site, and age of last interview as covariates; Analyses with COGA
were adjusted for familial clustering.
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Supplemental Table 4.3. Logistic regression models of the ordinal 4 level variable of time to
first cigarette after waking (>60, 31-60, 6-30, ≤5 minutes)

Metabolism Metric in
COGA Young Adult
Daily smokers (n=468)

Time to first cigarette after waking

Metabolism Metric in
COGEND Yong Adult Daily
Smokers (n=335)

Meta-analysis of results
of Daily Smokers

Beta

SE

p value

Beta

SE

p value

Beta

SE

p value

2.43

1.28

0.06

4.55

1.58

0.004

3.27

0.99

0.001

All models include sex, study site, and age of last interview as covariates; Analyses with COGA
were also adjusted for familial clustering.
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Supplemental Table 4.4. Logistic regression models of nicotine dependence that explore the
importance of time to first cigarette after waking
Metabolism Metric in
COGA Young Adult
Daily smokers (n=468)

Meta-analysis of results
of Daily Smokers

Beta

SE

p value

Beta

SE

p value

Beta

SE

p value

5.25

2.54

0.04

-18.66

15.7

0.23

4.63

2.25

0.07

-1.09

1.65

0.51

0.74

2.86

0.69

-0.28

1.23

0.82

Nicotine dependence conditioned on
time to first cigarette after waking
Nicotine dependence based on
adjusted FTND scores calculated
without the time to first cigarette
after waking question

Metabolism Metric in
COGEND Yong Adult Daily
Smokers (n=335)

All models include sex, study site, and age of last interview; Analyses with COGA were also
adjusted for familial clustering;
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4.11 SUPPLEMENTAL FIGURES

Metabolism Metric in COGEND (n=335)

Supplemental Figure 4.1. Distribution of CYP2A6 metabolism metric among COGA and
COGEND young adult daily smokers.
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Slow Metabolizer
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Proportion of sample

Proportion of sample
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Time to first cigarette after waking (minutes)
Young adult daily smokers in COGEND (n=335)

Time to first cigarette after waking (minutes)
Young adult daily smokers in COGA (n=468)

Supplemental Figure 4.2. Proportion of slow metabolizers among 4 categories of time to first
cigarette after waking among young adult daily smokers
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CHAPTER FIVE:
Common, low frequency, and rare coding variants in CHRNA5 contribute
to nicotine dependence in European and African Americans
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5.1 ABSTRACT

The functional nonsynonymous variant rs16969968 in the α5 nicotinic receptor subunit gene
(CHRNA5) is the strongest genetic risk factor for nicotine dependence in European Americans
(MAF=0.35), and contributes to risk in African Americans (MAF=0.06). To comprehensively
examine whether other CHRNA5 coding variation influences nicotine dependence risk, we
performed targeted sequencing on 1 582 nicotine dependent cases (Fagerstrom Test for Nicotine
Dependence score≥4) and 1 238 controls ages 25-45, with independent replication of common
and low frequency variants using 12 studies with exome chip data. Next-generation sequencing
with 180X coverage identified 24 nonsynonymous variants and 2 frameshift deletions in
CHRNA5, including 9 novel variants. Nicotine dependence was examined using logistic
regression and the variables sex, age, ancestry PCs, individual common variants (MAF≥0.05),
aggregate low frequency variants (0.05>MAF≥0.005), and aggregate rare variants (MAF<0.005).
Meta-analysis of primary results with replication studies containing 12 174 heavy and 11 290
light smokers confirmed robust independent risk effects of the only common variant
(rs16969968, European: OR=1.3, p=3.5x10-11; African: OR=1.3, p=0.01) and 3 low frequency
variants (aggregate term, European: OR=1.3, p=0.005; African: OR=1.4, p=0.0006). The
remaining 22 rare coding variants were associated with increased risk in the European American
primary sample (OR=12.9, p=0.01) and in the risk direction in African Americans (OR=1.5,
p=0.37). Beyond the well-studied rs16969968, we show that low frequency and rare CHRNA5
coding variants are independently associated with nicotine dependence risk. These newly
identified variants may have important health implications by influencing risk for smokingrelated diseases and response to cessation therapies.
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5.2 INTRODUCTION

Nicotine is the primary addictive component of tobacco products, and its physiological
effects are mediated largely through neuronal nicotinic acetylcholine receptors (Dani and De
Biasi, 2001). The α5/α3/β4 nicotinic subunit gene cluster on chromosome 15 harbors the
strongest and most replicated genetic risk factor for several smoking related traits. Specifically,
many independent studies demonstrated that rs16969968, a single nucleotide polymorphism in
the α5 subunit gene (CHRNA5), is associated with nicotine dependence, cigarettes per day,
smoking cessation, chronic obstructive pulmonary disease, and lung cancer (Amos et al, 2008;
Berrettini et al, 2008; Bierut et al, 2008; Caporaso et al, 2009; Chen et al, 2012a; Chen et al,
2009; Hung et al, 2008; Pillai et al, 2009; Saccone et al, 2007; Thorgeirsson et al, 2008).
Subsequent large-scale meta-analyses of European ancestry populations, where the rs16969968
minor allele is common (minor allele frequency (MAF)=0.35 in Exome Variant Server),
identified this region as unequivocally associated with heaviness of smoking (p=5.57x10-72) (Liu
et al, 2010; TAG, 2010; Thorgeirsson et al, 2010). Recently, rs16969968 was shown to have a
similar effect in African ancestry populations (Chen et al, 2012b; Saccone et al, 2009), where the
minor allele is less common (MAF=0.06 in Exome Variant
Server)(http://evs.gs.washington.edu/EVS/).
Beyond robust association studies across ancestry groups, functional studies support the
biological role of CHRNA5 and rs16969968 in the development of nicotine dependence. The
highest density of α5 subunits has been reported in the interpeduncular nucleus in the brain,
which receives input from the medial habenula (Hsu et al, 2013; Marks et al, 1992). Fowler et al.
(2011) demonstrated that mice with a null mutation for Chrna5 exhibited increased nicotine
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intake, which was “rescued” by re-expression of α5 in the medial habenula. Their findings
support the hypothesis that nicotine activates the habenulo-interpeduncular pathway through α5
containing receptors, limiting further nicotine intake. Genetic alterations that decrease the
function of α5 would therefore be expected to increase liability towards nicotine dependence.
Consistent with this hypothesis, the risk allele of rs16969968 has been shown to reduce receptor
function (Bierut et al, 2008; Kuryatov et al, 2011). Specifically, the A allele of rs16969968
causes an aspartic acid to asparagine change at position 398 in the α5 subunit, and expression of
this risk allele leads to decreased response to nicotine agonists in cell culture (Bierut et al, 2008)
as well as lower Ca2+ permeability and increased short term desensitization when incorporated
into certain neuronal nicotinic receptors (Kuryatov et al, 2011).
We hypothesized that additional low frequency and rare α5 coding variants may alter risk
for nicotine dependence. To comprehensively assess the relationship between CHRNA5 coding
variation and liability to nicotine dependence, we analyzed targeted sequence data from
approximately 3 000 nicotine dependent cases and non-dependent controls of European and
African descent. In addition, we used 12 studies with exome chip data for replication analysis of
the associations of common and low frequency variants with smoking behaviors found in our
primary data.
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5.3 MATERIALS AND METHODS

Primary Sample Ascertainment and Description
Subjects were recruited from the St Louis MO, Detroit MI, and Chicago IL metropolitan
areas through the Collaborative Genetic Study of Nicotine Dependence and the Genetic Study of
Nicotine Dependence in African Americans (Bierut et al, 2007; Saccone et al, 2007).
Community-based recruitment enrolled subjects aged 25-45 years old. All subjects underwent
comprehensive phenotypic assessments of smoking behaviors, including the Fagerstrom Test for
Nicotine Dependence (FTND). Nicotine dependent cases were required to be current smokers
and have an FTND score of 4 or higher. Non-dependent controls had smoked at least 100
cigarettes (to ensure exposure to nicotine) but had a lifetime maximum FTND score of 1.

Targeted sequencing of CHRNA5
DNA samples were derived from blood. The Center for Inherited Disease Research
(CIDR) performed next-generation targeted sequencing on genes strongly associated with
smoking, including CHRNA5. Details of the sequencing procedures and quality control measures
are provided in the Supplemental Methods. The mean on-target coverage was 180X, and
greater than 96% of on-target bases had a depth greater than 20X.

Evaluation of CHRNA5 coding variants
Genotypic data that passed initial quality control at CIDR were released to the Quality
Assurance/Quality Control analysis team at the University of Washington Genetics Coordinating
Center. CHRNA5 coding variants were identified by ANNOVAR (Wang et al, 2010) and then
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manually reviewed. This review involved examining summary statistics of the quality control
metrics, comparing the quality of novel variants with known variants from dbSNP and HapMap,
as well as inspecting alignments of selected samples with non-reference calls to pass or fail
variant sites. Seven samples were identified as low quality and omitted. Large genetic databases
(Abecasis et al, 2012) and protein prediction programs (Gonzalez-Perez and Lopez-Bigas, 2011)
were also used to assess identified coding variants.
Previously, Haller et al (2012) performed pooled sequencing of CHRNA5 in a sample that
also contributed 511 participants to targeted sequencing, identifying 4 CHRNA5 coding variants
beyond the well-studied rs16969968. Targeted sequencing found these 4 coding variants in the
same 34 people as pooled sequencing, demonstrating high concordance. Furthermore, targeted
sequencing also identified 6 additional singleton variants among the 511 people included in both
analyses. The high quality of the targeted sequencing data was further verified using the
HumanExome-12v1-1 array. All 2 820 individuals included in our primary analysis were
genotyped using this array, and the concordance for the common and low frequency coding
variants was 99.9%.

Data Analysis
A total of 1 432 European and 1 388 African Americans with targeted sequencing of
CHRNA5 and available smoking behaviors were examined in this analysis. Data were analyzed
using the Statistical Analysis System (SAS 9.3, Cary, NC, USA). Logistic regression was used to
model case-control status. European and African Americans were analyzed separately. Ancestry
groups were verified using EIGENSTRAT (Price et al, 2006) and previously collected genomewide arrays. HapMap populations were included as reference groups and linkage disequilibrium
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filters were applied. Ten ancestry-specific principal components (PCs) were also developed.
Examination of eigenvalues led us to include the first PC in our statistical analyses of both
ancestry groups. All models included the standard covariates of sex, age, and first ancestryspecific PC.
We analyzed all variants identified by ANNOVAR as functional. These coding variants
were divided into three classes based on the derived MAF in the entire sample: rare
(MAF<0.005), low frequency (0.05>MAF≥0.005), and common (MAF≥0.05). Visual
examination of the distribution of the allele frequencies in the sample (Figure S1) highlights a
natural grouping of these three frequency classes in this dataset.
In the primary analytic model, low frequency and rare variants were collapsed into an
aggregate low frequency variant term and aggregate rare variant term, respectively. Specifically,
individuals with at least one copy of the minor allele for any of the nonsynonymous and
frameshift variants were coded as 1 in each variant class (rare or low frequency) and individuals
without any minor allele copies in this class were coded as 0. This collapsing method was based
on a burden test (Li and Leal, 2008) to increase power to detect the cumulative effect of these
variant classes.
Main effects of the one common rs16969968 coding variant, aggregate low frequency
variants, and aggregate rare variants were analyzed together in a multivariate model of casecontrol status (multivariate model set 1). This approach was used to examine the effect of low
frequency and rare variants conditioned on the effect of the well-established common
rs16969968 variant. The primary logistic regression model was logit(p)=β0+βG1rs16969968+
βG2LowFrequencyTerm+βG3RareTerm+βCC where C is the vector of standard covariates.
In secondary analyses, we examined the three low frequency variants (rs2229961,
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rs80087508, rs79109919) as individual terms together with the common rs16969968 variant and
aggregate rare variants (multivariate model set 2). The secondary logistic regression model was
logit(p)=β0+βG1rs16969968+βG2rs2229961+βG3rs80087508+βG4rs79109919+βG5 RareTerm+βCC.
Because very few people were homozygous for the minor allele of the low frequency variants (05 individuals per variant), the heterozygous and homozygous individuals for each minor allele
were collapsed into a single group and compared to the homozygous individuals of the major
allele in these secondary analyses.

Explaining phenotypic variation
To examine the variation in nicotine dependence explained by CHRNA5 coding variants,
we used Nagelkerke’s adjusted R2 from logistic regression of case-control status (Nagelkerke,
1991). The variance in phenotype attributed to selected variants was derived as the R2
attributable to the full model minus the R2 attributable to the base model alone, including only
age, sex, and first ancestry-specific PC as predictors of outcome. European and African
American samples were analyzed separately. Each SNP or aggregate term was first examined
individually. We then examined the final multivariate model sets 1 and 2.

Replication samples
The common and low frequency CHRNA5 variants were assessed in 12 independent
replication datasets with smoking phenotypes and exome chip genotypes. Cigarettes smoked per
day (CPD), a proxy for nicotine dependence, was used as the outcome because FTND scores
were not available. Our replication analyses compared light smokers (CPD≤10) to heavy
smokers (CPD>20) aged 25-80 years old. Previous work has demonstrated that these thresholds
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of CPD agree with nicotine dependence defined by FTND (Berrettini et al, 2008; Stevens et al,
2008). European and African Americans were examined in separate logistic regression models
that were similar to the primary sample models without the rare variant term. Specifically, the
primary replication model was logit(p)=β0+βG1rs16969968+βG2LowFrequencyTerm+βCC, and
the secondary replication model was
logit(p)=β0+βG1rs16969968+βG2rs2229961+βG3rs80087508+ βG3rs79109919+βCC, where C is
the vector of standard covariates sex, age, ancestry-specific PCs, and field center (if applicable).
For each ancestry group, all replication studies were required to have at least 50 light and 50
heavy smokers to be included in analyses of that group.

Meta-Analysis
A series of meta-analyses involving the 12 replication datasets were performed using
PLINK (Purcell et al, 2007). First, beta values for the genetic factors obtained from
multivariable model sets 1 and 2 stratified by ancestry were meta-analyzed using weighting by
standard errors. Each of these meta-analyses were then repeated with the addition of the beta
from the primary dataset. Although examination of the Q statistic suggested no heterogeneity
across studies for any of the genetic factors in any of the meta-analyses (p>0.1), except
rs16969968 in European Americans (p=0.02)(Multivariable model sets 1 and 2 with and without
primary sample), to be consistent and conservative, all reported meta-analysis results are from
random effects models. Some of the individual low frequency variants in multivariable model
set 2 were found in a limited number of individuals in certain studies. An ancestry specific
sample was excluded from the meta-analysis of one of the low-frequency variants, if the minor
allele of that variant occurred less than 5 times in the sample.
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5.4 RESULTS

Variants identified in Sequencing
Sequencing initially identified 30 coding variants in CHRNA5, including 4 frameshift
deletions and 26 non-synonymous variants. Four variants failed the stringent quality control
metrics. Specifically, three variants were removed based on the review performed by the Quality
Assurance/Quality Control analysis team: p.Ala10fs had low sequencing depth, p.434_435del
was located at the wrong position, and p.Ile80Thr had a mean reference allele fraction
significantly deviated from 0.5. Finally, p.Ser6Leu was excluded because sequence information
was missing for 8% of the sample.
The remaining 26 CHRNA5 variants (24 nonsynonymous and 2 frameshift) included in
this analysis were rated as high quality in the manual review and were available in the entire
sample (details of these variants are listed in Supplemental Table 5.1 and Figure 5.1). The
majority are projected to be deleterious through protein prediction programs (Gonzalez-Perez
and Lopez-Bigas, 2011).

Common CHRNA5 variant
The only common coding variant identified was the previously well-studied rs16969968
located in the cytoplasmic domain of CHRNA5. In the primary sample, the rs1696968 minor
allele was associated with increased risk for nicotine dependence in European (OR=1.3,
p=0.003) and African Americans (OR=1.5, p=0.04) (Multivariate model set 1, Table 5.2).
Replication results from 12 independent studies support the hypothesis that the A allele of
rs16969968 increases risk for heaviness of smoking (Figure 5.2, Supplemental Tables 5.2-5.3).
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Meta-analyses combining results from the primary and replication datasets demonstrate the
robust role of rs16969968 (European: OR=1.3, p=3.7x10-11; African: OR=1.3, p=0.01).

Aggregate low frequency CHRNA5 variants
Three low frequency non-synonymous CHRNA5 variants were identified (Figure 1). To
increase power to detect associations, our primary analyses used an aggregate low frequency
variant term, comparing individuals with at least one minor allele of a low frequency variant to
those without any (6 individuals in the primary sample had 2 copies of a low frequency variant
and 1 individual had 2 different low frequency variants). In the primary Multivariate Model set
1, this aggregate low frequency term provided trending evidence for association in both
populations (European: OR=1.8, p=0.06; African: OR=1.4, p=0.07) (Table 5.2). Results from
the replication studies demonstrated a significant combined effect of the three low frequency
variants on heaviness of smoking (European: OR=1.2, p=0.02; African: OR=1.4, p=0.004)
(Figure 5.1, Supplemental Tables 5.2-5.3). The overall meta-analysis from the primary and
replication samples further illustrated the robust risk effect of the aggregate low frequency
variants in both European (OR=1.3, p=0.005) and African Americans (OR=1.4, p=0.0006).

Individual low frequency CHRNA5 variants
In secondary analyses using multivariate model set 2, we examined the independent
contributions of the three low frequency variants to nicotine dependence risk controlling for the
effect of other CHRNA5 coding variants. One of these low frequency variants was found
primarily in European Americans, and the other two were found almost exclusively in African
Americans (Table 5.2).
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The first low frequency variant rs2229961 causes a valine to isoleucine change at
position 134 in the extracellular domain. The minor allele principally occurred in European
Americans (MAF=0.02) and was rare in African Americans (MAF=0.002) (Table 5.2). In the
primary sample, all 51 individuals with a copy of rs2229961 also possessed at least one copy of
the well-established rs16969968 minor allele, suggesting that these two coding variants are
transmitted together. Controlling for the effect of rs16969968, the minor allele of rs2229961 was
in the risk direction in European (OR=1.7, p=0.1) and African Americans (OR=2.6, p=0.4).
Meta-analysis of these primary results and the independent replication samples provided strong
evidence that this variant contributed a risk effect in European Americans (OR=1.3, p=0.007)
where it predominantly occurs (Supplemental Table 5.4).
The minor allele of the second low frequency variant rs80087508 causes a lysine to
arginine transition at position 167 in the extracellular domain. This variant occurred exclusively
in African Americans in both the primary sequencing sample (MAF=0.01, Table 5.2) and in the
replication studies (Supplemental Table 5.5). This variant co-occurred with the common
rs16969968 minor allele in 5 out of 38 individuals in the primary sample. In multivariable model
set 2 controlling for other coding variants, the minor allele of rs80087508 trended in the risk
direction in African Americans (OR=2.1, p=0.06) (Table 2). Meta-analysis of these primary
results and the 12 independent replication samples provided evidence that this variant
contributed an independent risk effect in African Americans (OR=1.6, p=0.02) where it
exclusively occurred (Supplemental Table 5.5).
The final low frequency variant, rs79109919, causes a leucine to glutamine change at
amino acid position 363, which is located in the cytoplasmic domain (Figure 5.1). The minor
allele of rs79109919 was common in African Americans (MAF=0.06) and occurred in only one
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European American individual (MAF=0.0003) in the primary sample. Of the 158 individuals
who possessed at least one copy of the rs79109919 minor allele, 7 also possessed a copy of the
common rs16969968 risk allele and 1 possessed a copy of the low frequency rs80087508 variant,
suggesting the independent transmission of these variants. In the primary sample, the minor
allele of rs79109919 was in the risk direction in African Americans (OR=1.3, p=0.15) (Table
5.2). Meta-analysis of the primary and replication results provided strong evidence that this
variant contributed an independent risk effect in African Americans (OR=1.4, p=0.03) where it
primarily occurred (Supplemental Table 5.5).

Aggregate rare CHRNA5 variants
Sequencing identified 22 rare coding variants (MAF<0.5%), including 20
nonsynonymous variants and 2 frameshift deletions. These variants occurred throughout the
protein sequence (Figure 5.1). Each variant occurred in 1-4 individuals in the primary sample
(Supplemental Figure 5.1). Furthermore, 9 of the 22 rare variants were seen in a single
individual and were previously unreported in large reference datasets (Abecasis et al, 2012)
(Exome Variant Server) (Supplemental Table 5.1).
Because these variants occurred in only a limited number of individuals, we used a
collapsing burden test to assess their cumulative effect. Overall, 37 individuals possessed at least
1 rare variant, including 34 individuals with only one rare variant and 3 individuals (2 cases and
1 control) with 2 rare variants. In the primary sample, the aggregate rare variant term was
associated with a risk effect in the European Americans (OR=12.9, p=0.01) as 12/13 (92%)
individuals with at least one rare variant were cases (Table 5.2). In African Americans, the rare
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variant term was in the risk direction but not significant (OR=1.5, p=0.37) as 17/24 (71%) of the
individuals with at least one rare variant were cases.

Phenotypic variation accounted for by testing genetic factors
Nagelkerke’s adjusted R2 was used to assess the proportion of nicotine dependence
variation explained by individual SNPs and multivariable models in the primary sample (Table
5.3). The well-studied rs16969968 gave the single strongest R2 of 1.0% in European Americans
and a lower R2 of 0.4% in African Americans, where the variant is less common. In African
Americans, the two low frequency variants, rs80087508 and rs79109919, which each occurred
independently of rs16969968, gave R2 estimates of 0.3% and 0.1%, respectively. In European
Americans, the low frequency variant rs2229961 gave an R2 of 0.4%. Finally, the aggregate rare
variant term had a high R2 of 1.0% in European Americans and a lower R2 of 0.1% in African
Americans.
In multivariate models with common, low frequency, and rare CHRNA5 coding variants,
the overall phenotypic variance explained by the genetic variants was 2.4% in European
Americans and 1.0% in African Americans (multivariate model set 2, Table 5.3), supporting our
conclusion that substantial variation in liability to nicotine dependence is attributable to
CHRNA5 coding variation.
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5.5 DISCUSSION

Mounting evidence demonstrates that the functional rs16969968 variant in CHRNA5
strongly contributes to differences in the risk of developing nicotine dependence across diverse
populations (Chen et al, 2012b; Saccone et al, 2009). Here we show that multiple independent
CHRNA5 coding variants increase risk of nicotine dependence in European and African
Americans by examining targeted next-generation sequencing data of approximately 3 000
nicotine dependent cases and non-dependent controls, with replication of low frequency variants
using exome chip data in over 20 000 smokers.
Targeted sequencing of CHRNA5 provided evidence that common, low frequency, and
rare coding variants are independently associated with an increased risk of nicotine dependence,
extending previous sequencing studies of other smoking-related measures. Wessel et al (2010)
sequenced exons of CHRNA5 and other nicotinic receptors in 448 European American
participants enrolled in a smoking cessation trial. Using a weighted allele sharing test, this study
provided initial evidence that both common and rare variants contribute to level of FTND score
(pseudo-F=3.92, p=0.046). Haller et al (2012) used pooled sequencing to examine 5 nicotinic
receptor subunit genes (including CHRNA5) in 400 European and 352 African Americans from a
sample, which also contributed 511 participants to our study. Pooled sequencing identified 5
CHRNA5 coding variants. The well-studied rs16969968 was the only variant that exhibited a
significant effect on nicotine dependence (p<0.05), yet the minor allele of all but one of the
coding variants trended in the risk direction. Doyle et al (2014) sequenced 250 African American
heavy smokers and identified a few coding variants, including a novel frameshift deletion, which
the authors hypothesized leads to nonsense mediated decay. Our results build on these findings
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by sequencing a large, diverse, unrelated sample (n=2 820), which enabled us to identify many
coding variants of high quality (n=26), including 9 novel variants.
Using exome chip data from 12 studies containing over 10 000 heavy and 10 000 light
smokers, we confirmed that common and low frequency CHRNA5 coding variants identified
through targeted sequencing had a robust association with smoking behaviors. Previously, Vrieze
et al (2014) used the HumanExome BeadChip array to assess the effect of nonsynonymous
variants on addiction and behavioral disinhibition in a European ancestry sample. Examining 3
412 individuals from 1 694 families exposed to nicotine, this study identified 8 nonsynonymous
CHRNA5 variants. In single variant tests, rs16969968 (MAF=0.34) and rs2229961 (MAF=0.01)
had a trending risk effect with a bonferroni corrected threshold (p=0.015 and p=0.046,
respectively) on a composite nicotine dependence phenotype derived from factor analysis of
frequency (days per month), quantity (cigarettes per day), and symptoms of dependence. The 6
other nonsynonymous variants were rare (each occurred in 1-5 individuals), and the majority
were in the risk direction in single variant tests. When considered together using burden tests,
these rare variants did not reach the adjusted significance threshold (SKAT p-value=0.049). Our
replication study design of examining phenotypic extremes of smoking quantity (heavy vs light
smokers) using a large diverse sample facilitated the detection of strong associations between
common and low frequency nonsynonymous CHRNA5 variants and heaviness of smoking.
An important strength of our study was the large sample of African Americans (n=1 388),
a population often under-represented in genetic studies. Differences in the genetic architecture
of European and African ancestry groups indicate that distinct genetic factors contribute to
nicotine dependence in these populations. These differences are highlighted by the fact that the
well-established rs16969968 variant is substantially more common in European (MAF=0.35)
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than African Americans (MAF=0.06). We provide new evidence that two low frequency variants
primarily occurring in African Americans (rs80087508 and rs79109919) independently
contribute to nicotine dependence risk.
Since multiple independent CHRNA5 signals were identified, a critical question is what
proportion of phenotypic variance is explained by coding variation in this gene. Previous genetic
studies of complex traits have identified reproducible associations, but these findings often
explain only a modest proportion of phenotypic variance (Maher, 2008). For nicotine
dependence, rs16969968 is arguably the single strongest genetic risk factor in European ancestry
populations, and our results demonstrate that this variant only accounts for 1.0% of variance in
European Americans (Table 3). However, the addition of low frequency and rare coding variants
increased the estimated explained phenotypic variance in European Americans (R2=2.4%). In
African Americans, rs16969968 is less common and therefore explains a smaller proportion of
estimated phenotypic variance (R2=0.4%), and adding low frequency and rare coding variants
increased this estimate (R2=1.0%). These results highlight that low frequency and rare coding
variants, beyond the genome-wide significant common variant, increased the estimated variance
in nicotine dependence attributable to CHRNA5. An important next step is to examine variation
explained by these coding variants on biomarkers, which more closely resemble tobacco
exposure (Bloom et al, 2014; Munafo et al, 2012). Bloom et al (2014) found that rs16969968
explained four times more of the variance in carbon monoxide levels compared to self-reported
cigarette consumption. Low frequency and rare CHRNA5 coding variants will likely add to the
phenotypic variance of biomarkers and long-term disease.
The findings reported here have limitations. This analysis focused on coding variants in
CHRNA5 because the common nonsynonymous rs16969968 variant is associated with changes
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in receptor function (Bierut et al, 2008; Kuryatov et al, 2011) and we hypothesized that other
coding variants may have a similar effect. Several noncoding variants tagged by rs588765 have
been previously associated with changes in CHRNA5 mRNA expression levels in the brain
(Wang et al, 2009a; Wang et al, 2009b; Wang et al, 2013). Our analysis does not address the
contribution of noncoding CHRNA5 variation to nicotine dependence, which could influence our
observed findings. Another limitation is that our analysis is restricted to a single gene. Previous
studies (Saccone et al, 2010; Wessel et al, 2010) suggest that variation in other nicotinic
receptors contribute to nicotine dependence. Specifically, recent evidence supports that rare
variants in CHRNA3 and CHRNA4 are protective for nicotine dependence (Haller et al, 2012;
Slimak et al, 2014; Xie et al, 2011). However, CHRNA5 is clearly associated with nicotine
dependence, making it a high priority first gene for study.
In summary, this study provides evidence that common, low frequency, and rare coding
variants in CHRNA5 independently increase risk for nicotine dependence in both European and
African Americans as well as explain a substantial proportion of variance of this disease.
Importantly, we identify associations with nicotine dependence for three low frequency nonsynonymous variants, two of which almost exclusively occur in African Americans. From a
public health perspective, these newly identified CHRNA5 variants may have important
prognostic and therapeutic implications on an individual level. Beyond nicotine dependence,
previous studies show that rs16969968 is the strong genetic risk factor for lung cancer and
chronic obstructive pulmonary disease (Amos et al, 2008; Hung et al, 2008; Pillai et al, 2009;
Thorgeirsson et al, 2008) as well as influences response to smoking cessation therapies (Chen et
al, 2012a). An important next step is to test whether these low frequency and rare CHRNA5
coding variants similarly increase the risk of smoking-related diseases and response to smoking
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cessation. Expanding our knowledge of which genetic variants influence risk for long-term
diseases and response to treatments will inform personalized medical care for smokers.

139

5.6 ACKNOWLEDGEMENTS

I would like to acknowledge the co-authors of this study: Saccone NL, Johnson EO, Chen LS,
Culverhouse R, Doheny K, Foltz SM, Fox L, Gogarten SM, Hartz S, Hetrick K, Laurie CC,
Marosy B, Amin N, Arnett D, Bartz TM, Bertelsen S, Borecki IB, Brown MR, Chasman DI, van
Duijn CM, Feitosa MF, Fox ER, Franceschini N, Franco OH, Grove ML, Guo X, Hofman A,
Kardia SLR, Morrison AC, Musani SK, Psaty BM, Rao DC, Reiner AP, Rice K, Ridker PM,
Rose LM, Rotter JI, Schick UM, Schwander K, Uitterlinden AG, Vojinovic D, Wang JC, Ware
EB, Wilson G, Yao J, Zhao W, Breslau N, Hatsukami D, Stitzel J, Rice J, Goate A and Bierut LJ.

Please see supplement for acknowledgements listed by study.

Funding and Disclosure:
NIH grants and contracts supported the following studies and groups: COGEND
(P01CA89392), AAND(R01DA025888), CIDR (HHSN268201100011I), ARIC
(HHSN268201100005C, HHSN268201100006C, HHSN268201100007C,
HHSN268201100008C, HHSN268201100009C, HHSN268201100010C,
HHSN268201100011C, HHSN268201100012C, 5RC2HL102419, R01 HL118305), CHS
(HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080,
N01HC85081, N01HC85082, N01HC85083, N01HC85086, U01HL080295, R01HL087652,
R01HL105756, R01HL103612, R01HL120393, R01HL085251, R01HL068986, R01AG023629,
UL1TR000124, DK063491 ), COGA (U10AA008401), FamHS (R01HL118305, R01-DK089256), GENOA (HL054464, HL054457, HL054481, HL071917, NS041558, HL87660,
140

HL119443, HL118305), HyperGEN (HL54471, HL54472, HL54473, HL54495, HL54496,
HL54497, HL54509, HL54515, 2 R01 HL55673-12, R01 HL055673, R01 HL118305, U01
HL54473, R01 HL055673, R01 HL118305), MESA (N01-HC-95159, N01-HC-95160, N01-HC95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-RR-025005, R01-HL071051, R01-HL-071205, R01-HL-071250, R01-HL-071251, R01-HL-071252, R01-HL071258, R01-HL-071259, UL1-RR-025005, N02-HL-6-4278, UL1TR000124, DK063491),
WGHS (HL043851, HL080467, CA047988), WHI (HHSN268201100046C,
HHSN268201100001C, HHSN268201100002C, HHSN268201100003C,
HHSN268201100004C, HHSN271201100004C, R21HL123677-01, 1R01HL118305-01A1).

ERF was supported by the following grants: European Commission FP6 STRP grant number
018947 (LSHG-CT-2006-01947); European Community's Seventh Framework Program
(FP7/2007–2013, HEALTH-F4-2007-201413); Netherlands Organization for Scientific Research
and the Russian Foundation for Basic Research (NWO-RFBR 047.017.043); ZonMw grant
(project 91111025).

EO was supported by T32GM07200, UL1TR000448, TL1TR000449, and F30AA023685.
LJB was supported by U19CA148172.
LJB, AG, and JCW as well as the spouse of NLS are listed as inventors on Issued U.S. Patent
8,080,371,“Markers for Addiction” covering the use of certain SNPs in determining the
diagnosis, prognosis, and treatment of addiction.
JAS has received support from Pfizer, Inc.
141

NA is supported by the Hersenstichting Nederland (project number F2013(1)-28).
OHF Franco works in ErasmusAGE, a center for aging research across the life course funded by
Nestlé Nutrition (Nestec Ltd.); Metagenics Inc.; and AXA. Nestlé Nutrition (Nestec Ltd.);
Metagenics Inc.; and AXA had no role in design and conduct of the study; collection,
management, analysis, and interpretation of the data; and preparation, review or approval of the
manuscript.
BMP serves on the DSMB of a clinical trial funded by the device manufacturer (Zoll LifeCor)
and on the Steering Committee of the Yale Open Data Access Project funded by Johnson &
Johnson.
The other authors declare no conflicts of interest.

142

5.7 REFERENCES

Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP). Seattle, WA.
Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, et al (2012). An
integrated map of genetic variation from 1,092 human genomes. Nature 491(7422): 5665.
Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, et al (2008). Genome-wide association
scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nature
genetics 40(5): 616-622.
Berrettini W, Yuan X, Tozzi F, Song K, Francks C, Chilcoat H, et al (2008). Alpha-5/alpha-3
nicotinic receptor subunit alleles increase risk for heavy smoking. Molecular psychiatry
13(4): 368-373.
Bierut LJ, Madden PA, Breslau N, Johnson EO, Hatsukami D, Pomerleau OF, et al (2007).
Novel genes identified in a high-density genome wide association study for nicotine
dependence. Human molecular genetics 16(1): 24-35.
Bierut LJ, Stitzel JA, Wang JC, Hinrichs AL, Grucza RA, Xuei X, et al (2008). Variants in
nicotinic receptors and risk for nicotine dependence. The American journal of psychiatry
165(9): 1163-1171.
Bloom AJ, Hartz SM, Baker TB, Chen LS, Piper ME, Fox L, et al (2014). Beyond cigarettes per
day. A genome-wide association study of the biomarker carbon monoxide. Annals of the
American Thoracic Society 11(7): 1003-1010.

143

Caporaso N, Gu F, Chatterjee N, Sheng-Chih J, Yu K, Yeager M, et al (2009). Genome-wide
and candidate gene association study of cigarette smoking behaviors. PloS one 4(2):
e4653.
Chen LS, Baker TB, Piper ME, Breslau N, Cannon DS, Doheny KF, et al (2012a). Interplay of
genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking
cessation success. The American journal of psychiatry 169(7): 735-742.
Chen LS, Saccone NL, Culverhouse RC, Bracci PM, Chen CH, Dueker N, et al (2012b).
Smoking and genetic risk variation across populations of European, Asian, and African
American ancestry--a meta-analysis of chromosome 15q25. Genetic epidemiology 36(4):
340-351.
Chen X, Chen J, Williamson VS, An SS, Hettema JM, Aggen SH, et al (2009). Variants in
nicotinic acetylcholine receptors alpha5 and alpha3 increase risks to nicotine dependence.
American journal of medical genetics Part B, Neuropsychiatric genetics : the official
publication of the International Society of Psychiatric Genetics 150B(7): 926-933.
Dani JA, De Biasi M (2001). Cellular mechanisms of nicotine addiction. Pharmacology,
biochemistry, and behavior 70(4): 439-446.
Doyle GA, Chou AD, Saung WT, Lai AT, Lohoff FW, Berrettini WH (2014). Identification of
CHRNA5 rare variants in African-American heavy smokers. Psychiatric genetics 24(3):
102-109.
Fowler CD, Lu Q, Johnson PM, Marks MJ, Kenny PJ (2011). Habenular alpha5 nicotinic
receptor subunit signalling controls nicotine intake. Nature 471(7340): 597-601.

144

Gonzalez-Perez A, Lopez-Bigas N (2011). Improving the assessment of the outcome of
nonsynonymous SNVs with a consensus deleteriousness score, Condel. American journal
of human genetics 88(4): 440-449.
Haller G, Druley T, Vallania FL, Mitra RD, Li P, Akk G, et al (2012). Rare missense variants in
CHRNB4 are associated with reduced risk of nicotine dependence. Human molecular
genetics 21(3): 647-655.
Hsu YW, Tempest L, Quina LA, Wei AD, Zeng H, Turner EE (2013). Medial habenula output
circuit mediated by alpha5 nicotinic receptor-expressing GABAergic neurons in the
interpeduncular nucleus. The Journal of neuroscience : the official journal of the Society
for Neuroscience 33(46): 18022-18035.
Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, et al (2008). A
susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes
on 15q25. Nature 452(7187): 633-637.
Kuryatov A, Berrettini W, Lindstrom J (2011). Acetylcholine receptor (AChR) alpha5 subunit
variant associated with risk for nicotine dependence and lung cancer reduces
(alpha4beta2)(2)alpha5 AChR function. Molecular pharmacology 79(1): 119-125.
Li B, Leal SM (2008). Methods for detecting associations with rare variants for common
diseases: application to analysis of sequence data. American journal of human genetics
83(3): 311-321.
Liu JZ, Tozzi F, Waterworth DM, Pillai SG, Muglia P, Middleton L, et al (2010). Meta-analysis
and imputation refines the association of 15q25 with smoking quantity. Nature genetics
42(5): 436-440.

145

Maher B (2008). Personal genomes: The case of the missing heritability. Nature 456(7218): 1821.
Marks MJ, Pauly JR, Gross SD, Deneris ES, Hermans-Borgmeyer I, Heinemann SF, et al (1992).
Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment.
The Journal of neuroscience : the official journal of the Society for Neuroscience 12(7):
2765-2784.
Munafo MR, Timofeeva MN, Morris RW, Prieto-Merino D, Sattar N, Brennan P, et al (2012).
Association between genetic variants on chromosome 15q25 locus and objective
measures of tobacco exposure. Journal of the National Cancer Institute 104(10): 740748.
Nagelkerke N (1991). A note on a general definition of teh coefficient of determination.
Biometrika 78(3): 691-692.
Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, Need AC, et al (2009). A genome-wide
association study in chronic obstructive pulmonary disease (COPD): identification of two
major susceptibility loci. PLoS genetics 5(3): e1000421.
Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D (2006). Principal
components analysis corrects for stratification in genome-wide association studies.
Nature genetics 38(8): 904-909.
Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al (2007). PLINK: a
tool set for whole-genome association and population-based linkage analyses. American
journal of human genetics 81(3): 559-575.

146

Saccone NL, Schwantes-An TH, Wang JC, Grucza RA, Breslau N, Hatsukami D, et al (2010).
Multiple cholinergic nicotinic receptor genes affect nicotine dependence risk in African
and European Americans. Genes, brain, and behavior 9(7): 741-750.
Saccone NL, Wang JC, Breslau N, Johnson EO, Hatsukami D, Saccone SF, et al (2009). The
CHRNA5-CHRNA3-CHRNB4 nicotinic receptor subunit gene cluster affects risk for
nicotine dependence in African-Americans and in European-Americans. Cancer research
69(17): 6848-6856.
Saccone SF, Hinrichs AL, Saccone NL, Chase GA, Konvicka K, Madden PA, et al (2007).
Cholinergic nicotinic receptor genes implicated in a nicotine dependence association
study targeting 348 candidate genes with 3713 SNPs. Human molecular genetics 16(1):
36-49.
Slimak MA, Ables JL, Frahm S, Antolin-Fontes B, Santos-Torres J, Moretti M, et al (2014).
Habenular expression of rare missense variants of the beta4 nicotinic receptor subunit
alters nicotine consumption. Frontiers in human neuroscience 8: 12.
Stevens VL, Bierut LJ, Talbot JT, Wang JC, Sun J, Hinrichs AL, et al (2008). Nicotinic receptor
gene variants influence susceptibility to heavy smoking. Cancer epidemiology,
biomarkers & prevention : a publication of the American Association for Cancer
Research, cosponsored by the American Society of Preventive Oncology 17(12): 35173525.
TAG (2010). Genome-wide meta-analyses identify multiple loci associated with smoking
behavior. Nature genetics 42(5): 441-447.

147

Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, et al (2008). A variant
associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature
452(7187): 638-642.
Thorgeirsson TE, Gudbjartsson DF, Surakka I, Vink JM, Amin N, Geller F, et al (2010).
Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nature
genetics 42(5): 448-453.
Vrieze SI, Feng S, Miller MB, Hicks BM, Pankratz N, Abecasis GR, et al (2014). Rare
nonsynonymous exonic variants in addiction and behavioral disinhibition. Biological
psychiatry 75(10): 783-789.
Wang JC, Cruchaga C, Saccone NL, Bertelsen S, Liu P, Budde JP, et al (2009a). Risk for
nicotine dependence and lung cancer is conferred by mRNA expression levels and amino
acid change in CHRNA5. Human molecular genetics 18(16): 3125-3135.
Wang JC, Grucza R, Cruchaga C, Hinrichs AL, Bertelsen S, Budde JP, et al (2009b). Genetic
variation in the CHRNA5 gene affects mRNA levels and is associated with risk for
alcohol dependence. Molecular psychiatry 14(5): 501-510.
Wang JC, Spiegel N, Bertelsen S, Le N, McKenna N, Budde JP, et al (2013). Cis-regulatory
variants affect CHRNA5 mRNA expression in populations of African and European
ancestry. PloS one 8(11): e80204.
Wang K, Li M, Hakonarson H (2010). ANNOVAR: functional annotation of genetic variants
from high-throughput sequencing data. Nucleic acids research 38(16): e164.
Wessel J, McDonald SM, Hinds DA, Stokowski RP, Javitz HS, Kennemer M, et al (2010).
Resequencing of nicotinic acetylcholine receptor genes and association of common and
rare variants with the Fagerstrom test for nicotine dependence.
148

Neuropsychopharmacology : official publication of the American College of
Neuropsychopharmacology 35(12): 2392-2402.
Xie P, Kranzler HR, Krauthammer M, Cosgrove KP, Oslin D, Anton RF, et al (2011). Rare
nonsynonymous variants in alpha-4 nicotinic acetylcholine receptor gene protect against
nicotine dependence. Biological psychiatry 70(6): 528-536.

149

5.8 TABLES
Table 5.1. Characteristics of primary sample
European American
(n=1 432)

African American
(n=1 388)

cases

controls

cases

controls

728

704

854

534

37 (25-45)

36 (25-45)

36 (25-45)

36 (25-45)

Female

386 (53%)

482 (68%)

514 (60%)

321 (60%)

Male

342 (47%)

222 (32%)

340 (40%)

213 (40%)

a

6.49 (4-10)

0.02 (0-1)

6.21 (4-10)

0.33 (0-1)

1.94 (0-3)

0.01 (0-1)

1.11 (0-3)

0.03 (0-1)

Sample, n
Age, mean (range)
Sex

FTND score, mean (range)
b

CPD category, mean (range)

a

FTND is the Fagerstrom test for Nicotine Dependence

b

CPD is categorical cigarettes per day (1 is ≤10, 2 is 11-20, 3 is 21-30, 4 is >30);
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Table 5.2. The effect of common, low frequency, and rare CHRNA5 coding variants on nicotine
dependence in primary sample
European Americans (n=1 432)
Variant Class

Variant

MAF*

OR (95% CI)

African Americans (n=1 388)

pvalue

MAF

0.003

0.058

0.06

0.071

0.01

0.009

0.003

0.058

0.10

0.002

OR (95% CI)

pvalue

Multivariable Model set 1
Common
Low Frequency
Rare

rs16969968
Aggregate
term**
Aggregate
term

0.355
0.016
0.005

1.27
(1.08-1.49)
1.81
(0.97-3.42)
12.90
(1.66-100.54)

1.46
(1.02-2.07)
1.35
(0.98-1.87)
1.47
(0.60-3.59)

0.04
0.07
0.40

Multivariable Model set 2
Common

Low Frequency

Rare

1.28
(1.09-1.50)
1.71
(0.91-3.23)

rs16969968

0.355

rs2229961

0.016

rs80087508

0***

.

.

0.014

rs79109919

0.0003
****

.

.

0.057

Aggregate
term

0.005

12.91
(1.66-100.66)

0.01

0.009

1.42
(1.00-2.03)
2.57
(0.28-23.91)
2.00
(0.94-4.27)
1.22
(0.86-1.75)
1.51
(0.62-3.68)

0.05
0.40
0.07
0.26
0.37

Multivariable model set 1 includes rs16969968, the aggregate low frequency variant term, and
the aggregate rare variant term:
Multivariable model set 2 includes rs16969968, rs2229961, rs800087508, rs79109919, and the
aggregate rare variant term;
All models adjusted for sex, age, and first ancestry-specific PC as covariates;
*MAF stands for minor allele frequency; **for aggregate terms, the MAF was estimated by the
dividing the number of people with at least one low frequency/rare variant by 2 times the total
number of people; *** rs80087508 is non-polymorphic in European Americans; **** Because
the minor allele of rs79109919 occurred less than 5 times in European Americans, the OR and pvalue are not presented.
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Table 5.3. Variation in nicotine dependence risk explained by selected variants and multivariate
models in primary sample
European Americans (n=1 432)
Variant Class
Common

Low Frequency

Rare

Variant
MAF

R

2

African Americans (n=1 388)

p-value

MAF

R

2

p-value

rs16969968

0.355

1.0%

0.001

0.058

0.4%

0.04

aggregate term

0.016

0.5%

0.02

0.071

0.3%

0.06

rs2229961

0.016

0.4%

0.03

0.002

0.1%

0.24

rs80087508

0

.

.

0.014

0.3%

0.07

rs79109919

0.0003

0.2%

0.15

0.057

0.1%

0.34

aggregate term

0.005

1.0%

0.0009

0.009

2.3%

1.2x10

Multivariable model set 1
Multivariable model set 2

2.4%

0.1%

0.37

-5

0.8%

0.04

-5

1.0%

0.07

5.5 x10

R2 is the Nagelkerke’s adjusted R2 difference from logistic regression, comparing the base model
with intercept, sex, age, and ancestry specific PCs to models with genetic variants;
Each individual variant and aggregate term was examined first by itself and then we examined
the final multivariate model sets 1 and 2;
Multivariable model set 1 includes rs16969968, the aggregate low frequency variant term, and
the aggregate rare variant term:
Multivariable model set 2 includes rs16969968, rs2229961, rs800087508, rs79109919, and the
aggregate rare variant term;
p-values calculated by taking the difference between the -2logliklihoods in the base model and
those with variants as a chi-square statistic.
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5.9 FIGURES

Figure 5.1. Protein Schematic of CHRNA5 nonsynonymous and frameshift variants. Bold
underline indicates the only common variant (MAF>5%); Bold indicates low frequency variants
(5%>MAF≥0.5%); Other variants are rare (MAF<0.5%).
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Figure 5.2. Forest plots showing the primary sample, replication samples, and random effects
meta-analyses from Multivariable model set 1. (a) rs1696998 in European Americans; (b)
aggregate low frequency variant term in European Americans; (c) rs1696998 in African
Americans; (d) aggregate low frequency variant term in African Americans.
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5.10 SUPPLEMENTAL METHODS

Targeted sequencing of CHRNA5
Custom baits were designed using Agilent’s web-based design tool eArray
(https://earray.chem.agilent.com/earray) to capture regions with 50 kilobases on either side of the
gene. For library preparation, samples were placed on 96-well plates that were stratified by
case/control status, recruitment study site, ethnicity, and sex. A range of 500ng to 1ug of
genomic DNA was sheared using the Covaris E-210 instrument using modified parameters for
shearing (DutyCycle=10%, Intensity=4, Cycles per Burst=200, time=80sec). Libraries were
prepared according to the Agilent protocol (SureSelectXT Target enrichment for Illumina
Multiplexed Sequencing Protocol v1.1.1). Amplification of the libraries prior to and post capture
were performed using the Kapa Biosystems HiFi HotStart Ready Mix. Samples were clustered
for sequencing using the Illumina cBOT Cluster Generation system. One hundred base pairs
paired end sequencing was performed on the Illumina HiSeq 2000 platform v3 chemistry. FastQ
files were aligned with BWA (Li and Durbin, 2010) to the 1000 genomes phase 2 (GRCh37)
human genome reference (Abecasis et al, 2012). GATK2.3-9 was used for base quality
recalibration and local realignment. Unified Genotyper was used for multi-sample calling and
VQSR for variant filtering. All samples had 96-SNP barcode genotyping for sample identity
tracking and concordance checking.

Quality Control Measures
Data quality was systematically evaluated using a robust alignment and variant calling
workflow implemented by CIDR (http://www.cidr.jhmi.edu/index.html). Over 100 quality
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control metrics were evaluated in real time to quickly identify potential errors and implement
fixes throughout the sequencing process. Briefly, samples underwent pretesting with 96 SNP
barcode panels, and more than 50% of samples also had previously acquired GWAS array data to
verify sample identity and quality. Sample sex was confirmed by examining normalized read
depth on the X and Y chromosomes. 64 duplicate samples and 65 HapMap controls were also
used to assess the quality of variant calls.

References:
Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, et al (2012). An
integrated map of genetic variation from 1,092 human genomes. Nature 491(7422): 5665.
Li H, Durbin R (2010). Fast and accurate long-read alignment with Burrows-Wheeler transform.
Bioinformatics (Oxford, England) 26(5): 589-595

156

5.11 SUPPLEMENTAL REPLICATION STUDY DESCRIPTIONS

Atherosclerosis Risk Communities Study (ARIC)
The ARIC study has been described in detail previously.1 Men and women aged 45-64 years at
baseline were recruited from four communities: Forsyth County, North Carolina; Jackson,
Mississippi; Minneapolis, Minnesota; and Washington County, Maryland. A total of 15,792
individuals, predominantly White and African American, participated in the baseline
examination in 1987-1989, with three additional triennial follow-up examinations and a fifth
exam in 2011. Informed consent was obtained from all participants, and this project was
approved by the Institutional Review Boards of all participating institutions. The current analysis
included 3 366 European Americans (1 859 Heavy smokers and 1 507 Light smokers) and 922
African Americans (214 heavy smokers and 708 light smokers) with available Illumina Infinium
Human Exome Array v1.0 data.2

Reference:
1. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and
objectives. Am J Epidemiol 129, 687-702 (1989).
2. Grove, M.L., Yu, B., Cochran, B.J., Haritunians, T., Bis, J.C., Taylor, K.D., Hansen, M.,
Borecki, I.B., Cupples, L.A., Fornage, M., et al. (2013). Best practices and joint calling of the
HumanExome BeadChip: the CHARGE Consortium. PLoS ONE 8, e68095.
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Cardiovascular Health Study (CHS)
This is a population-based cohort study of risk factors for the development and progression of
cardiovascular disease in older adults sponsored by the by the NHLBI.1 Between 1989 and 1990,
this study recruited 5201 adults ages 65 and older from four U.S. communities, and recruited an
additional predominately African-American cohort of 687 people in 1992-1993. Subjects
received annual clinic follow-up and semi-annual phone calls. Informed consent was obtained
from all participants, and this project was approved by the Institutional Review Boards of all
participating institutions. The current analysis included 1 370 European Americans (513 Heavy
smokers and 857 Light smokers) and 312 African Americans (50 heavy smokers and 262 light
smokers) with available Illumina HumanExome BeadChip v1.0 data.

Reference:
1. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio
TA, Mittelmark MB, Newman A. The Cardiovascular Health Study: design and rationale. Ann
Epidemiol. 1991; 1(3):263-76

Collaborative Study on the Genetics of Alcoholism (COGA)
COGA was initiated in 1989 as a large, family study designed to identify genes that contribute to
alcohol use disorders and related behaviors funded by the National Institute on Alcohol Abuse
and Alcoholism.1,2 Alcoholic probands were recruited from treatment facilities from seven sites
across the US. Family members of these probands were invited to participate and a set of
comparison families was also drawn from the same communities. COGA has gathered detailed,
standardized data on study participants, including diagnostic, genetic, and neurophysiological
158

assessments. COGA continues to enroll young participants from these families in a longitudinal
study to examine the development of substance use disorders. Informed consent was obtained
from all participants, and this project was approved by the Institutional Review Boards of all
participating institutions. The current analysis included 340 European Americans (208 Heavy
smokers and 132 Light smokers) with available Affymetrix Axiom Exome 319 array data.

References:
1. Begleiter H, Reich T, Hesselbrock V, Porjesz B, Li T, Schuckit M, Edenberg H, Rice J (1995)
The Collaborative Study on the Genetics of Alcoholism. Alcohol Health Res World 19:228–236
2. Edenberg, H. J. (2002) The Collaborative Study on the Genetics of Alcoholism:
an update. Alcohol Res Health 26, 214-218.,

Erasmus Rucphen Family study (ERF)
This is a family-base cohort study, which is part of the Genetic Research in isolated Populations
(GRIP) program.1,2 The goal of this study is to identify genetic risk factors in the development of
complex disorders within a genetically isolated population in the southwest of the Netherlands.
In this study, 22 couples that had at least 6 children baptized in the community church from
1850-1900 were identified. All living descendants and their spouses were invited to participate.
Study population includes ~3000 individuals. All data were collected between 2002 and 2005.
Subjects received extensive clinical evaluations at a research center within the community.
Informed consent was obtained from all participants, and this project was approved by the
Institutional Review Boards of all participating institutions. The current analysis focused on 215
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Europeans (77 Heavy smokers and 138 Light smokers) with available Illumina HumanExome
chip v1.1 data.

References:
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isolate: the Erasmus Rucphen Family study J Med Genet 2008;45:572-577

Family Heart Study (FamHS)
The FamHS (https://dsgweb.wustl.edu/fhscc/ ) is a multi-center, population-based study of
genetic and nongenetic determinants of coronary heart disease (CHD), atherosclerosis, and
cardiovascular risk factors. This study began in 1992 with the ascertainment of 1,200 families,
half randomly sampled and half selected because of an excess of CHD or risk factor
abnormalities as compared with age- and sex-specific population rates.1 The families, with
approximately 6,000 subjects, were sampled from four population-based parent studies. The
participants attended a first clinic visit between the years 1994-1996 and a broad range of
phenotypes was assessed in the general domains of CHD, atherosclerosis, cardiac and vascular
function, inflammation and hemostasis, lipids and lipoproteins, blood pressure, diabetes and
insulin resistance, pulmonary function, diet, habitual physical activity, anthropometry, medical
history and medication use. Approximately 8 years later, 2,756 European American (EA)
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subjects belonging to the 510 of the largest and most informative pedigrees were invited for a
second clinical visit (2002-04). The most important CHD risk factors were measured again.
Medical history and medication use was updated. Informed consent was obtained from all
participants, and this project was approved by the Institutional Review Boards of all participating
institutions. FamHS participants were genotyped on the HumanExome Bead-Chip v.1.0
(Illumina) and jointly called at the University of Texas Health Science Center at Houston.
Informed consent was obtained from all participants, and this project was approved by the
Institutional Review Boards of all participating institutions. The current analysis included 991
European Americans (550 Heavy smokers and 441 Light smokers) from the first clinical visit in
which has a total of 3,868 subjects with exome data.
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Williams R. NHLBI Family Heart Study: objectives and design. Am J Epidemiol. 1996 Jun 15;
143(12):1219-28.

Genetic Epidemiology Network of Arteriopathy (GENOA)
This is one of four research networks that form the NHLBI Family Blood Pressure Program.1,2
The overall goal of GENOA is to elucidate the genetics of hypertension and its arteriosclerotic
target-organ damage, including macrovascular and microvascular complications in heart, brain,
kidneys, and peripheral arteries. From 1995 to 2000, two cohorts were ascertained through
sibships in which at least 2 siblings had essential hypertension diagnosed prior to 60 years of
age. All siblings were invited to participate. Approximately 80% of participants received a
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follow-up exam between 2000 and 2005. Informed consent was obtained from all participants,
and this project was approved by the Institutional Review Boards of all participating institutions.
The current analysis included 539 European Americans (258 Heavy smokers and 281 Light
smokers) and 371 African Americans (73 Heavy smokers and 298 Light smokers) with available
Illumina Infinium HumanExome BeadChip v1.1 data.
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treatment and control in the Genetic Epidemiology Network of Arteriopathy (GENOA) study.
Am J Med. 2004 May 15; 116(10):676-81.

Hypertension Genetics Epidemiology Network (HyperGEN)
This is one of four research networks that form the NHLBI Family Blood Pressure Program.1,2
The goal of HyperGEN is to identify major genetic determinants of hypertension and to study
possible interactions between genetic and non-genetic factors in defined populations. African
American and non-Hispanic white hypertensive siblings along with available parents and
untreated adult offspring were recruited from 5 field centers across the US. Preference in
ascertainment and recruitment was given to sibships with a least one subject with severe
hypertension. Informed consent was obtained from all participants, and this project was approved
by the Institutional Review Boards of all participating institutions. The current analysis included
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715 African Americans (97 Heavy smokers and 618 Light smokers) with available Affymetrix
Genome-Wide Human SNP Array 6.0 and 5.0 data.
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Epidemiol. 2000 Aug;10(6):389-400.

Jackson Heart Study (JHS)
This is a large, community-based, observational study to understand factors that influence heart
disease and other illnesses in African Americans funded by the NHLBI and the Office of
Research on Minority Health at NIH.1 JHS is an expansion of the ARIC study site in Jackson,
Mississippi. Since its inception in 1998, 5 301 African American men and women have been
enrolled in this study from urban and rural areas in the Jackson, Mississippi metropolitan area.
The study focused on individuals ages 35-84, except in the family cohort where individuals 21 to
34 were also eligible. Three back-to-back cohort clinical exams were performed (2000-2004,
2005-2009, and 2009-2012), providing extensive longitudinal data. Informed consent was
obtained from all participants, and this project was approved by the Institutional Review Boards
of all participating institutions. The current analysis included 495 African Americans (102 Heavy
smokers and 393 Light smokers) with available Illumina HumanExome Chip v1.0 data.
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Multi-Ethnic Study of Atherosclerosis (MESA)
This population-based cohort study was initiated in July 2000 to investigate the prevalence,
correlates, and progression of subclinical cardiovascular disease.1 A total of 6 814 asymptomatic
individuals’ ages 45-84 years olds were recruited from 6 field centers across the US. Each
participant received an extensive clinical exam and blood samples were collected to test
biochemical and genetic risk factors. Informed consent was obtained from all participants, and
this project was approved by the Institutional Review Boards of all participating institutions. The
current analysis included 819 European Americans (369 Heavy smokers and 450 Light smokers)
and 546 African Americans (101 Heavy smokers and 445 Light smokers) with available Illumina
HumanExome Chip v1.0
data.

Reference:
1. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P,
Jacob DR Jr, Kronmal R, Liu K, Nelson JC, O'Leary D, Saad MF, Shea S, Szklo M, Tracy RP.
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Rotterdam Study Cohort 1 (RS1)
The Rotterdam Study is a prospective, population-based cohort study to determine the
occurrence of cardiovascular, neurological, ophthalmic, endocrine, hepatic, respiratory, and
psychiatric diseases in elderly people.1 Subjects were recruited from Ommoord, a suburb of
Rotterdam, in three different cohorts. The initial cohort (RS1) began in 1990 with 7 983
individuals aged 55 and older with follow-up visits in 1994-1995, 1997-1999, 2002-2004, and
2009-2011. All participants were interviewed at home and received an extensive set of clinical
examinations, including imaging and sample collection for molecular and genetic analyses.
Informed consent was obtained from all participants, and this project was approved by the
Institutional Review Boards of all participating institutions. The current analysis included 1 235
Europeans (535 Heavy smokers and 700 Light smokers) with available Illumina HumanExome
beadchip v1.0 data.
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Rotterdam Study: 2014 objectives and design update. Eur J Epidemiol. 2013 Nov;28(11):889926. doi: 10.1007/s10654-013-9866-z. Epub 2013 Nov 21. PubMed PMID: 24258680.

Women’s Genomic Health Study (WGHS)
The Women’s Genome Health Study (WGHS) is a prospective cohort of initially healthy, female
North American health care professionals at least 45 years old at baseline representing
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participants in the Women’s Health Study (WHS) who provided a blood sample at baseline and
consent for blood-based analyses. 1 The WHS was a 2x2 trial beginning in 1992-1994 of vitamin
E and low dose aspirin in prevention of cancer and cardiovascular disease with about 10 years of
follow-up. Since the end of the trial, follow-up has continued in observational mode. Additional
information related to health and lifestyle were collected by questionnaire throughout the WHS
trial and continuing observational follow-up. Informed consent was obtained from all
participants, and this project was approved by the Institutional Review Boards of all participating
institutions. The current analysis included 6 540 European Americans (4 924 Heavy smokers and
1 616 Light smokers) that had the common rs16969968 variant genotyped on the Illumina
HumanHap300 Duo”+” and the three low frequency CHRNA5 variants genotyped on the
Illumina exome v.1.1 chip.
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women. Clin Chem. 2008 Feb;54(2):249-55. Epub 2007 Dec 10. PubMed PMID: 18070814.

Women’s Health Initiative (WHI)
The WHI is a long-term national health study focused on strategies for preventing heart disease,
breast and colorectal cancer, and osteoporotic fractures in postmenopausal women. Between
1993 and 1998, 161 808 postmenopausal women were enrolled from 40 clinical centers in either
a clinical trial (68 132) or an observation study (93 676).1-4 The clinical trials were designed to
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test the effects of postmenopausal hormone therapy, diet modification, as well as calcium and
vitamin D supplements on disease outcomes. The observation study examined the relationship
between lifestyle, environmental, medical, and other risk factors on specific measures of health.
Recruitment was done through mass mailing to age-eligible women obtained from voter
registration, driver’s license and Health Care Financing Administration or insurance lists, with
target recruitment of a socio-demographically diverse population. WHI participants were also
invited to participate in an extension study with follow-up through 2010. Informed consent was
obtained from all participants, and this project was approved by the Institutional Review Boards
of all participating institutions. The current analysis included 4 076 European Americans (2 065
Heavy smokers and 2 011 Light smokers) and 610 African Americans (117 Heavy smokers and
493 Light smokers) with available Illumina HumanExome BeadChip v1exome chip data.
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5.12 SUPPLEMENTAL TABLES
Supplemental Table 5.1. Characteristics of 26 high quality CHRNA5 coding variants identified by targeted sequencing of 1 582
Nicotine dependent cases and 1 238 controls.
Position of
variants

dbSNP
identifier

Coding
Change

Protein
Change

a

Study MAF , allele count

European
Ancestry
(n=1,432)

Frameshift
Deletions
chr15:78882
385..788823
86
chr15:78885
495..788855
00

c.653delG

p.Trp218fs

c.1308_131
2del
p.436_438del

frequency
class in
analysis

African
Ancestry
(n=1,388)
0.0004,
1(A1)/2775(R)

Rare

0.0004,
1(A1)/2775(R)

Rare

Exome Sequencing Project
MAF, allele count

AA

EA

0.000,
1(A1)/4263(R)

0.001,
5(A1)/8247(R)

Phase 1 1000
Genomes
MAF, allele
count

Condel
Score
(Class)

Nonsynony
mous SNVs
chr15:78873
239

c.193G>C

p.Val65Leu

chr15:78873
288

c.242C>T

p.Ser81Phe
p.Val97Ile

chr15:78879
017
rs148722844 c.289G>A
chr15:78880
752

rs2229961

c.400G>A

p. Val134Ile

chr15:78882
176
rs201563436 c.443C>T

p.Thr148Met

0.0003,
1(C)/2863(G)

0.016,
46(A)/2818(G)

Rare

0.712
(deleterious)

0.0004,
1(T)/2775(C)

Rare

0.861
(deleterious)

0.0007,
2(A)/2774(G)

Rare

0.002,
5(A)/2771(G)
0.0004,
1(T)/2775(C)

0.0003,
1(T)/2863(C)

0.000,
1(A)/4391(G)

0.386
(neutral)

Low
0.003,
0.019,
0.006,
0.905
frequency 14(A)/4378(G) 165(A)/8421(G) 13(A)/2171(G) (deleterious)
Rare

0.000,
8585(C)/1(T)

0.966
(deleterious)

Rare

0.000,
8583(C)/3(T)

1.000
(deleterious)

0.014,
Low
0.019,
39(G)/2737(A) frequency 4308(A)/84(G)

0.000,
8585(A)/1(G)

0.005,
0.790
2174(A)/10(G) (deleterious)

chr15:78882
221
rs55863434

c.488C>T p.Pro163Leu

chr15:78882
233
rs80087508

c.500A>G p. Lys167Arg

chr15:78882
389

c.656A>C

p.Glu219Ala

0.0003,
1(C)/2863(A)

Rare

chr15:78882
446
rs61742337

c.713C>T p.Pro238Leu

0.0007,
2(T)/2862(C)

Rare
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0.449
(neutral)
0.000,
8584(C)/2(T)

0.883
(deleterious)

chr15:78882
478
rs137878726 c.745C>A p.Leu249Met

0.001,
4(A)/2772(C)

Rare

0.000,
2(A)/4390(C)

0.841
(deleterious)

chr15:78882
529
rs138719535 c.796T>A

p.Phe266Ile

0.001,
3(A)/2773(T)

Rare

0.001,
3(A)/4389(T)

0.858
(deleterious)

chr15:78882
682
rs116099178 c.949C>G p. Leu317Val

0.001,
4(G)/2772(C)

Rare

0.001,
4389(C)/3(G)

chr15:78882
694
rs74865777

c.961A>G p.Met321Val

chr15:78882
733

c.1000G>A p.Ala334Thr

0.0007,
2(G)/2862(A)
0.0004,
1(A)/2775(G)

0.001,
2182(C)/2(G)

0.411
(neutral)

Rare

0.643
(deleterious)

Rare

0.473
(deleterious)

chr15:78882
809
rs79721430 c.1076C>T p. Thr359Met

0.0003,
1(T)/2863(C)

Rare

0.000,
8584(C)/2(T)

0.000,
2183(C)/1(T)

0.027
(neutral)

chr15:78882
821
rs79109919 c.1088T>A p.Leu363Gln

0.0003,
1(A)/2863(T)

0.058,
Low
0.052,
160(A)/2616(T) frequency 228(A)/4164(T)

0.001,
5(A)/8581(T)

0.021,
0.871
46(A)/2138(T) (deleterious)

chr15:78882
0.355,
0.058,
0.062,
0.349,
0.175,
925
rs16969968 c.1192G>A p.Asp398Asn 1016(A)/1848(G) 161(A)/2615(G) Common 274(A)/4118(G) 2993(A)/5593(G) 383(A)/1801(G)

0.018
(neutral)

chr15:78882
934
rs76766434 c.1202C>T p.Arg401Cys

0.458
(neutral)

0.0007,
2(T)/2774(C)

Rare

0.002,
4385(C)/7(T)

chr15:78882
935
rs141180754 c.1202G>A p.Arg401His

0.001,
3(A)/2773(G)

Rare

0.001,
3(A)/4389(G)

chr15:78882
953

0.0004,
1(T)/2775(C)

Rare

0.005
(neutral)

Rare

0.910
(deleterious)

c.1220C>T

p.Ile407Thr

chr15:78885
462
rs202052590 c.1274A>G p.Gln425Arg
chr15:78885
464
rs150329151 c.1276G>A

0.0003,
1(T)/2863(C)

0.0003,
1(G)/2863(A)

p.Val426Ile

chr15:78885
574
rs76071148 c.1386T>A p.His462Gln

0.0007,
2(A)/2862(T)

chr15:78885
579

0.0003,
1(G)/2863(A)

a

c.1391A>G p.Gly464Glu

0.0004,
1(A)/2775(G)

Rare

0.000,
1(A)/4391(G)

0.0007,
2(A)/2774(T)

Rare

0.000,
2(A)/4390(T)

Rare

MAF is minor allele frequency.
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0.000,
8585(C)/1(T)

0.000,
2183(C)/1(T)

0.025
(neutral)

0.746
(deleterious)
0.000,
2(A)/8584(T)

0.076,
166(A)/2018(T)

0.340
(neutral)
0.88(deleterious)

Supplemental Table 5.2. Random effects meta-analysis results for multivariate model set 1 in European Americans
rs16969968

Primary sample***
Replication Studies
ARIC
CHS
COGA
ERF
FamHS
GENOA
MESA
RS1
WGHS
WHI
Meta-analysis
Overall****
Meta-analysis

Heavy
Smokers
728

Light
Smokers
704

1859
513
209
138
550
258
369
535
4924
2065
11420

1507
857
133
77
441
281
450
700
1616
2011
8073

12148

8777

MAF*
0.36

OR
1.27

p-value
0.003

0.33
0.34
0.33
0.36
0.34
0.37
0.33
0.30
0.34
0.36

1.44
1.07
1.53
0.86
1.45
1.39
1.30
1.16
1.29
1.33
1.27

1.03E-09
0.48
0.06
0.25
0.0006
0.01
0.02
0.11
4.17E-09
3.05E-09
3.51E-09

1.27

3.69E-11

Aggregate low frequency
variants
MAF**
OR
p-value
0.02
1.81
0.06
0.02
0.02
0.02
0.02
0.01
0.01
0.01
0.01
0.02
0.02

1.20
1.25
0.49
1.26
1.03
0.97
1.35
1.73
1.45
1.05
1.23

0.41
0.50
0.24
0.38
0.95
0.96
0.48
0.17
0.01
0.77
0.02

1.27

0.005

Multivariable model set 1 includes rs16969968 and the aggregate low frequency variant term:
All models adjusted for sex, age, PCs, and field center (if appropriate) as covariates;
*MAF stands for minor allele frequency; **For the aggregate low frequency variant terms, the MAF was calculated by the dividing
the number of people with at least one low frequency/rare variant by the total number of people by 2; ***Primary sample compared
nicotine dependent cases versus controls instead of heavy versus light smokers; ****Overall meta-analysis included the primary and
replication samples.
171

Supplemental Table 5.3. Random effects meta-analysis results for multivariate model set 1 in African Americans
rs16969968

Primary sample***
Replication Studies
ARIC
CHS
GENOA
HyperGEN
JHS
MESA
WHI
Meta-analysis
Overall****
Meta-analysis

Heavy
Light
Smokers Smokers MAF*
854
534
0.06
214
50
73
97
102
101
117
754

708
262
298
618
393
445
493
3217

1608

3751

0.06
0.08
0.05
0.05
0.06
0.07
0.06

OR
1.46

p-value
0.04

1.36
2.14
1.93
1.00
0.73
0.89
1.22
1.24

0.20
0.03
0.09
1.00
0.42
0.73
0.49
0.10

1.30

0.01

Aggregate low frequency
variants
MAF** OR
p-value
0.06 1.46
0.04
0.07
0.06
0.08
0.07
0.07
0.06
0.05

1.49
1.20
1.38
1.11
2.14
0.89
1.33
1.42

0.09
0.73
0.35
0.76
0.01
0.73
0.39
0.004

1.40

0.0006

Multivariable model set 1 includes rs16969968 and the aggregate low frequency variant term:
All models adjusted for sex, age, PCs, and field center (if appropriate) as covariates;
*MAF stands for minor allele frequency; **For the aggregate low frequency variant terms, the MAF was calculated by the dividing
the number of people with at least one low frequency/rare variant by the total number of people by 2; ***Primary sample compared
nicotine dependent cases versus controls instead of heavy versus light smokers; ****Overall meta-analysis included the primary and
replication samples.
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Supplemental Table 5.4. Random effects meta-analysis results for multivariate model set 2 in European Americans
Heavy
Smoker
Light
s
Smokers
Primary
sample***
Replication
Studies
ARIC
CHS
COGA
ERF
FamHS
GENOA
MESA
RS1
WGHS
WHI
Meta-analysis
Overall****
Meta-analysis

rs16969968

rs2229961

rs79109919

MAF*

OR

p-value

MAF

OR

p-value

MAF

OR

p-value

728

704

0.36

1.28

0.003

0.02

1.71

0.10

0.0003**

.

.

1859
513
209
138
548
258
369
535
4924
2065
11418

1507
856
133
77
438
281
450
700
1616
2011
8069

0.33
0.34
0.33
0.36
0.34
0.37
0.33
0.30
0.34
0.36

1.44
1.07
1.52
0.86
1.46
1.39
1.29
1.16
1.29
1.34
1.27

1.07E-09
0.49
0.06
0.25
0.0005
0.01
0.02
0.11
6.15E-09
2.14E-09
3.72E-09

0.02
0.02
0.02
0.02
0.01
0.01
0.01
0.01
0.02
0.02

1.20
1.27
0.60
1.26
1.02
0.97
1.45
1.73
1.38
1.05
1.23

0.41
0.47
0.43
0.38
0.97
0.96
0.40
0.17
0.03
0.79
0.02

0.0003**
0
0.002**
0
0
0
0.0008**
0
0.0004
0.0006

.
.
.
.
.
.
.
.
3.50
2.01
2.60

.
.
.
.
.
.
.
.
0.21
0.45
0.16

12146

8773

1.28

3.60E-11

1.26

0.007

2.60

0.16

Multivariable model set 2 includes rs16969968, rs229961, rs8008750, and rs79109919. However, rs8008750 was non-polymorphic in
European Americans in all of the studies so it is not included in this table.
All models adjusted for sex, age, PCs, and field center (if appropriate) as covariates;
*MAF stands for minor allele frequency; ** Because the minor allele of rs79109919 occurred less than 5 times in the primary sample,
ARIC, COGA, and MESA, these results were not included in the meta-analyses; ***Primary sample compared nicotine dependent
cases versus controls instead of heavy versus light smokers; ****Overall meta-analysis included the primary and replication samples.
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Supplemental Table 5.5. Random effects meta-analysis results for multivariate model set 2 in African Americans
rs16969968
rs2229961
rs8008750
rs79109919
Heavy
Light
Smokers Smokers MAF* OR p-value MAF
OR p-value MAF OR p-value MAF OR p-value
Primary
sample***
Replication
Studies
ARIC
CHS
GENOA
HyperGEN
JHS
MESA
WHI
Meta-analysis
Overall****
Meta-analysis

854

534

0.06

1.46

0.04

0.002

2.57

0.40

0.01 2.00

0.07

0.06 1.22

0.26

214
50
73
97
102
101
117
754

708
262
298
618
393
445
493
3217

0.06
0.08
0.05
0.05
0.06
0.07
0.06

1.49
2.11
1.79
1.03
0.89
0.87
1.22
1.29

0.11
0.04
0.14
0.92
0.78
0.68
0.50
0.04

0.005
0.005
0.001**
0.001**
0.004**
0.009
0.005

0.51
1.60
.
.
.
1.00
0.94
0.85

0.46
0.73
.
.
.
1.00
0.94
0.77

0.02
0.01
0.01
0.02
0.02
0.02
0.01

1.04
1.74
1.35
1.13
1.31
2.16
1.79
1.43

0.94
0.54
0.74
0.84
0.62
0.14
0.35
0.12

0.05
0.04
0.07
0.05
0.05
0.05
0.04

1.70
0.93
1.10
1.12
3.16
0.88
1.10
1.39

0.03
0.92
0.81
0.78
0.001
0.75
0.81
0.06

1608

3751

1.33

0.005

1.06

0.91

1.56

0.02

1.36

0.03

Multivariable model set 2 includes rs16969968, rs229961, rs8008750, and rs79109919.
All models adjusted for sex, age, PCs, and field center (if appropriate) as covariates.
*MAF stands for minor allele frequency; ** Because the minor allele of rs2229961 occurred less than 5 times in GENOA,
HyperGEN, and JHS, these results were not included in the meta-analysis; ***Primary sample compared nicotine dependent cases
versus controls instead of heavy versus light smokers; ****Overall meta-analysis included the primary and replication samples.

174

5.13 SUPPLEMENTAL FIGURE
Supplemental Figure 5.1. Twenty-six CHRNA5 coding variants ordered based on minor allele
frequency
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CHAPTER SIX:
Future steps to understand the role of targeted genes in substance use disorders
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6.1 SUMMARY OF THE DISSERTATION

Overall, this dissertation illustrates the discovery potential of analyses focused on
dissecting associations between genome-wide significant genes and substance use disorders.
First, I illustrate in chapter 2 that many previously identified candidate genes are not strongly
associated with alcohol dependence in a large genome wide association (GWA) study,
highlighting that GWA studies can clarify the role of candidate genes for substance use
disorders. I then conducted several hypothesis-driven analyses focused on three functional
candidate genes (ADH1B, CYP2A6, and CHRNA5) that have reached genome-wide levels for
alcoholism or smoking in GWA studies. By incorporating important environmental factors,
critical developmental periods, and rare coding variants, I refined associations between these
genes and substance use behaviors. In chapter 3, I showed that the high-risk environment of peer
drinking eliminates the protective effect of an ADH1B variant on adolescent drinking milestones.
In chapter 4, I demonstrated that a CYP2A6 metabolism metric was not associated with smoking
initiation or daily smoking, but slow metabolism was associated with increased risk of nicotine
dependence among daily smokers. Finally, in chapter 5, I provided evidence that low frequency
and rare CHRNA5 coding variants contribute an independent risk effect to nicotine dependence.
These findings add insight into the biological mechanisms that lead to alcohol and nicotine use
disorders, two diseases with substantial public health implications in the US and worldwide
(CDC, 2014, Stahre et al., 2014, WHO, 2014b, WHO, 2014a).
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6.2 FUTURE DIRECTIONS

Replication in independent samples
These studies provide new evidence for the role of targeted genes in the development of
substance use disorders. Although some of these new findings were replicated in independent
samples (e.g. role of metabolism metric on nicotine dependence in chapter 4 and effect of low
frequency variants on smoking behaviors in chapter 5), an appropriate replication sample was not
available to verify all of the association findings in this dissertation. Replication of these
findings in independent samples using a variety of different populations would provide
additional evidence supporting the robustness and generalizability of our conclusions.

Experiments to understand biological mechanisms
Association findings from the analyses presented in this dissertation have led to new
hypotheses about the role of genetic variation in the development of substance use disorders. An
important next step is to experimentally test these hypotheses. For example, in chapter 6, I
identified several low frequency and rare CHRNA5 coding variants that confer an independent
risk for nicotine dependence beyond the common rs16969968 variant. Previous biological
studies of rs16969968 have shown that the risk A allele leads to decreased response to nicotine
agonists in cell culture experiments (Bierut et al., 2008) as well as lower Ca2+ permeability and
increased short term desensitization when incorporated into certain neuronal nicotinic receptors
expressed in Xenopus laevis oocytes (Kuryatov et al., 2011). Similar electrophysiology patchclamp experiments could be used to assess the functional effects of the newly identified low
frequency and rare CHRNA5 coding variants. Biological studies could inform our understanding
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of the mechanisms by which these identified genetic variants alter risk for substance use
disorders.

Test additional hypotheses and build composite risk scores
By focusing on variation in ADH1B, CYP2A6, and CHRNA5, we have developed a
framework for understanding how environmental factors, developmental periods, and rare
variants influence the roles of targeted genes in substance use disorders. This framework could
also be used to test additional hypotheses that build on the findings presented in this dissertation.
For example, beyond peer drinking, parental monitoring is a critical environment for the
development of adolescent drinking behaviors and twin studies suggest that family factors
modify heritable variation in youth alcohol involvement (Kendler et al., 2011, Miles et al., 2005).
Based on our observation that the high-risk environment of adolescent peer drinking diminishes
the protective effect of an ADH1B variant in chapter 2, we would hypothesize that the social
context of low parental monitoring would likewise decrease the protective effect of metabolizing
variants on early adolescent drinking behaviors. Similar hypothesis-driven studies of robust
genetic factors may add to our knowledge of the complex role of these genes on the development
of substance use behaviors.
Future studies may also seek to expand on these findings with individual genes to build
composite risk scores that predict the development of substance use disorders based on several
genetic and environmental factors. Accurate prediction tools could inform intervention strategies
that aim to identify at-risk individuals and prevent disease progression.
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Translation to long-term disease risk and tailored therapies
In this dissertation, I identified and refined associations between robust genes and
substance use disorders. An important next step is to extend these findings to long-term disease
risk as well as response to treatments. Excessive alcohol use and persistent tobacco smoking are
both associated with increased risk of a variety of chronic diseases, and it is important to
understand how observed genetic associations with substance use disorders translate to related
disease risk and response to treatments. For example, previous studies show that rs16969968 is
the strongest genetic risk factor for lung cancer and chronic obstructive pulmonary disease
(Amos et al., 2008, Hung et al., 2008, Pillai et al., 2009, Thorgeirsson et al., 2008) as well as
influences response to different smoking cessation therapies (Chen et al., 2012). An important
next step is to test whether these low frequency and rare CHRNA5 coding variants similarly
increase the risk of smoking-related diseases and response to cessation treatment. This
knowledge could inform personalized medical care of individuals who suffer from substance use
disorders.
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